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Abstract 
The rate of human immunodeficiency virus (HIV) infection shows a diminishing trend at 
the global level while it shows increasing in intensity of mortality, morbidity, and burden 
in Sub-Saharan Africa. The intertwined behavioral, demographic, and clinical 
determinants fueled the incidence of infections in Zambian women. The purpose of this 
study was to determine the association between demographic, behavioral, and clinical 
determinants with HIV serostatus in Zambian women. With the conceptual framework of 
the World Health Organization’s Commission for Social Determinants of Health (CSDH) 
and quantitative method of MANOVA, this study examined Zambian Demographic 
Health Survey data for Zambian women of two age groups (adolescent and adult). The 
findings showed statistically significant results in the association between HIV serostatus 
and self-perceived HIV risk for both groups and in the association between education and 
HIV serostatus among women in both groups (adolescents and adults). However, there 
was no statistically significant association between behavioral, demographic, and clinical 
determinants of HIV serostatus. These findings imply the need to conduct prospective 
studies to curb this deadly virus and improve community health for women in Africa.   
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Chapter 1: Introduction to the Study  
Overview 
Human immunodeficiency virus (HIV) is a virus that infects humans and leads to 
acquired immune deficiency syndrome (AIDS), a lethal disease that weakens the immune 
system (Centers for Disease Control and Prevention, 2015). Approximately 37 million 
people are living with human immunodeficiency virus (HIV); about 2 million new 
infections and almost 1 million AIDS-related deaths occur each year (Schwetz & Fauci, 
2019). 
Although infection rates of HIV/AIDS are decreasing globally, both infection 
rates and prevalence have increased in Zambia and other Sub-Saharan African countries 
(Ranganathan et al., 2017; Wakeham et al., 2017). Meager HIV prevention and 
insufficient access to clinical services are common issues in countries in this region. 
Ninety percent of HIV infections in this region is due to poor condom use and multiple 
sexual partners (Muzyamba, Broaddus, & Campbell, 2015). In Zambia, in particular, 
about 14% of people aged 18–49 years have HIV (Amoyaw, Kuuire, Boateng, Asare-
Bediako, & Ung, 2015).  
The purpose of this study is to assess the associations between the behavioral, 
demographic, and clinical determinants of HIV serostatus in Zambian women. Findings 
from this study may inform methods to reduce new infections, deter mortality and 
morbidity associated with AIDS, and improve the quality of life for Zambian women 
living with HIV/AIDS. 
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Background 
Behavioral, demographic, and clinical factors affect HIV serostatus, as well as the 
risk acquisition levels, spread, and epidemic of HIV (Qiao, Zhang, Li, & Menon, 2018). 
Behavioral factors include the use of condoms and the number of sexual partners. 
Demographic determinants of HIV serostatus include age, sex, marital status, location, 
and education. Finally, clinical factors include HIV diagnosis, individuals’ relationships 
with their health care providers, and access to counseling. Some factors serve as barriers 
to HIV testing and treatment, whereas others (such as access to counseling) facilitate the 
prevention of the disease. 
Behavioral Factors 
 Behavioral factors, such as multiple sexual partners, unprotected sex, 
nondisclosure of HIV positive serostatus, increased HIV new infections, and spread of 
HIV for adolescent and adult women, contribute to the prevalence of HIV (Pinchoff, 
Boyer, Mutombo, Chowdhuri, & Ngo, 2017; Salam et al., 2016). Mathur et al. (2018) 
found that, for heterosexual couples, having multiple sexual partners alone contributed to 
15% of female HIV-positive cases and increased HIV prevalence by 4% for 15- to 19-
year-old Zambian women. Other researchers have found a positive correlation between 
the rate of HIV infection and sexual risk-taking in adolescent and adult women (Toska et 
al., 2017). For 15- to 49-year-olds, risky sexual behaviors led to greater increases in HIV 
prevalence for women than for men (Hegdahl, Fylkesnes, & Sandøy, 2016). 
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Demographic Factors 
HIV serostatus correlates with demographic variables such as age, sex, and 
location. For example, Chanda-Kapata, Klinkenberg, Maddox, Ngosa, & Kapata (2016) 
and McCarraher et al. (2018) found that women have higher HIV infection rates than 
men. Furthermore, Okawa et al. (2018) found that female adolescents did not understand 
HIV transmission methods, even though they were concerned about it affecting their 
future marriages. Kharsany and Karim (2016) found consistent increases in HIV infection 
and transmission rates in Zambian women aged 18–49 years; these rates are six times 
higher than those of similarly aged Zambian men. Both HIV/AIDS infection rates and 
HIV-associated deaths are higher among women (Amoyaw et al., 2015). Research also 
suggests that the risk level is higher in urban areas than in rural areas (Chanda-Kapata et 
al., 2016; McCarraher et al., 2018). 
People who are unaware of their HIV status are at an elevated risk of spreading 
the virus. In Zambia, HIV affects 2.9% of the population, and an estimated 1.2 million 
women aged 15–49 years have HIV (Qiao, Zhang, Li, & Menon, 2018). 
Problem Statement 
Zambia is a country in the Sub-Saharan African region that has people living with 
a high burden of human immunodeficiency virus (HIV) infections and sustained HIV 
transmission. Zambia is one of the ten countries that have one of the highest HIV 
prevalence in the world, accounting for 4% of the worldwide HIV infected people 
(Kharsany & Karim, 2016). The different types of HIV serostatus (HIV positive 
serostatus, HIV negative serostatus, unknown HIV serostatus) indicated an association 
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with risk of HIV infection and rate of mortality, and rate of morbidity with other sexually 
transmitted diseases (Moodley, 2017). Researchers in their literature review found age 
and education critical to awareness of HIV serostatus and the risk of HIV transmission 
due to risky behaviors (inconsistent condom use) for adolescent and adult women at 
personal, interpersonal, and community levels (Okawa et al., 2018; Omonaiye, Kusljic, 
Nicholson, & Manias, 2018; Pinchoff, Boyer, Mutombo, Chowdhuri, & Ngo, 2017). 
Toska et al. (2017) have shown that multiple sexual partners in HIV infected women 
(aged 18-49 years) correlated with an increase in HIV infection and a decrease in HIV 
status awareness and concluded the lack of conclusive evidence on the main HIV risky 
sexual behaviors succumbing individual to HIV infections. The HIV epidemics and 
prevalence due to risky sexual behaviors were higher for 15-49-years older women 
compared to men with the same age group (Hegdahl, Fylkesnes, & Sandøy, 2016). The 
nonawareness of HIV status has been a risk in contributing to the spread of new HIV 
infections at a scale of 2.9% and an estimated 1.2 million HIV infected Zambian women 
aged 15-49 years (Qiao, Zhang, Li, & Menon, 2018). Demographic factors such as age, 
gender, and location are also associated with HIV serostatus at a higher rate of infection 
for females than males and more prevalence in urban communities than rural 
communities (Chanda-Kapata et al., 2016); McCarraher et al., 2018). 
In a cross-sectional study, Okawa e al. (2018) reported the association of knowledge 
deficiency to HIV transmission in female adolescents with unknown status and concerns 
of HIV infected female adults due to nondisclosure of HIV positive status. Their findings 
suggested a future study for in-depth understanding and more conclusive results on the 
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level of association of HIV serostatus and demographic factors (age, location, gender). 
Previous studies suggested having more data for drawing conclusive findings on 
behavioral determinants and demographic determinants to understand challenges and 
facilitators of HIV serostatus of Zambian women (Qiao, Zhang, Li, & Menon, 2018).  
Kharsany and Karim (2016) reported a continuous increase of HIV infection in Zambia 
women of 15-24 years at a scale of six times compared to men of similar age range and 
recommended future research focusing on risky sexual behaviors and knowledge gap in 
HIV serostatus awareness at a community level. Systematic and meta-analyses showed a 
limitation of research on behavioral factors associated to the HIV status of adolescents in 
Zambia and other Sub-Saharan Africa because of the studies focus on specific sexual 
behaviors (Ssewanyana et al., 2018). Moreover, systematic reviews recommended further 
studies on clinical factors such as linkage to treatment and commencement of 
antiretroviral medications to increase testing and treating and advance HIV treatment 
outcomes (Mark et al., 2017; Williams, Renju, Ghilardi, & Wringe, 2017).  Therefore, 
this study assesses the association between the behavioral determinants (condom use, 
sexual partners, and HIV self-perceived risk), demographic determinants, and clinical 
determinants (use of HIV services GOV, use of HIV services clinic, and use of HIV 
services NGO) with HIV serostatus and infer findings for possible recommendations to 
specific populations of Zambia, such as adolescent women from age 18 to 24 years and 
adult women from age 25 to 49 years. 
6 
 
Purpose of the Study 
The purpose of this study is to assess the association between behavioral and 
demographic determinants with HIV serostatus in Sub-Saharan Africa and propose 
preventive measures to reduce the burden of HIV, eliminate new infections, and promote 
community health of Zambian adolescent and adult women. I plan to understand the 
association of behavioral and demographic determinants with HIV serostatus and the 
impact of positive social change specifically on Zambian adolescent and adult women 
and possibly make a generalizable recommendation for women in similar settings who 
reside in Sub-Saharan African Countries. 
Research Questions and Hypotheses 
Research Question 1: What is the association between behavioral determinants 
and HIV serostatus of Zambian female adolescents from ages 18 to 24 years?  
Ho1: There is no statistically significant association between behavioral 
determinants and HIV serostatus of Zambian female adolescents from ages 18 to 24 
years.    
Ha1: There is a statistically significant association between behavioral 
determinants and HIV serostatus of Zambian female adolescents from ages 18 to 24 
years.  
Research Question 2: What is the association between behavioral determinants 
and HIV serostatus of Zambian female adults from ages 25 to 49 years?  
Ho2: There is no statistically significant association between behavioral 
determinants and HIV serostatus of Zambian female adults from ages 25 to 49 years. 
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Ha2: There is a statistically significant association between behavioral 
determinants and HIV serostatus of Zambian female adults from ages 25 to 49 years.  
Research Question 3: What is the association between demographic determinants 
and HIV serostatus of Zambian female adolescents from ages 18 to 24 years?  
Ho3: There is no statistically significant association between demographic 
determinants and HIV serostatus of Zambian female adolescents from ages 18 to 24 
years.   
Ha3: There is a statistically significant association between demographic 
determinants and HIV serostatus of Zambian female adolescents from ages 18 to 24 
years.  
Research Question 4: What is the association between demographic determinants 
and HIV serostatus of Zambian female adults from ages 25 to 49 years?  
Ho4: There is no statistically significant association between demographic 
determinants and HIV serostatus of Zambian female adults from ages 25 to 49 years.  
Ha4: There is a statistically significant association between demographic 
determinants and HIV serostatus of Zambian female adults from ages 25 to 49 years. 
Research question 5. What is the association between clinical determinants and 
HIV serostatus of Zambian female adolescents from ages 18 to 24? 
Ho5: There is no statistically significant association between clinical determinants 
and that of HIV serostatus of Zambian female adolescents from ages 18 to 24 years.  
Ha5: There is a statistically significant association between clinical determinants 
and HIV serostatus in Zambian female adolescents from ages 18 to 24 years.  
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Research question 6. What is the association between clinical determinants and 
HIV serostatus of Zambian female adults from ages 25 to 49 years? 
Ho6: There is no statistically significant association between clinical determinants 
and that of HIV serostatus of Zambian female adults from ages 25 to 49 years.  
Ha6: There is a statistically significant association between  
clinical determinants and HIV serostatus in Zambian female adults from ages 25 to 49 
years.  
Research Question 7: What is the synergistic association between behavioral, 
demographic, and clinical determinants and that of HIV serostatus of Zambian 
adolescents from ages 18 to 24 years?  
Ho7: There is no statistically significant synergistic association between 
behavioral, demographic, and clinical determinants and that of HIV serostatus of 
Zambian female adolescents from ages 18 to 24 years.  
Ha7: There is a statistically significant synergistic association between behavioral, 
demographic, and clinical determinants and that of HIV serostatus in Zambian female 
adolescents from ages 18 to 24 years.  
Research Question 8: What is the synergistic association between behavioral, 
demographic, and clinical determinants and that of HIV serostatus of Zambian adults 
from age 25 to 49 years? 
Ho8: There is no statistically significant synergistic association between 
behavioral, demographic, and clinical determinants and that of HIV serostatus of 
Zambian female adults from age 25 to 49 years.  
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Ha8: There is a statistically significant synergistic association between behavioral, 
demographic, and clinical determinants and that of HIV serostatus in Zambian female 
adults from age 25 to 49 years. 
Conceptual Framework of the Study 
The World Health Organization’s Commission for Social Determinants of Health 
(CSDH) is a conceptual framework used for this study. The CSDH reviewed extensive 
evidence on social determinants of health and addressed the behavioral and demographic 
factors that impact health equity and the community health (Östlin et al., 2011). This 
conceptual framework addresses population health and understands the community health 
inequalities at the global level in wealthy and developing countries (Venkatapuram, 
2010). Moreover, WHO conceptual framework had been applied in low and middle-
income countries and proved sufficient to measure health inequalities and involve 
policymakers for health promotion of the population health (Guerra, Borde, & de Snyder, 
2016). Mtenga, Pfeiffer, Tanner, Geubbels, & Merten (2018)  have shown that there is a 
connection between men’s involvement in multiple sexual partners and HIV acquiring to 
the extent women have a higher risk of HIV infection at individual levels.  In addition to 
men’s several partners, factors such as women’s economic dependence, alcohol drinking 
behaviors, and lack of financial certainty increased the risk of HIV to women (Mtenga, 
Pfeiffer, Tanner, Geubbels, & Merten, 2018). The authors created a literature review on 
the social determinants of HIV health in different social, economic, and demographic 
settings. The authors revealed that differences in gender, age, and race, sexual behaviors 
(multiple sexual partners, sex worker, noncondom use), low literacy level, 
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unemployment, low economic status were risk factors for increased rate of HIV infection 
and HIV transmission (Araújo, Duarte, & Pereira, 2018). 
Nature of the Study 
The nature of this study will be an inferential study. For this study, health data on 
“Survey of HIV Status and Fertility Preference in Sub-Saharan Africa 2009-2010 
(ICPSR 36718)” will be used for secondary data analysis. The survey included female 
adolescents (18-24 years) and female adult Zambians (25-49 years). The behavioral, 
demographic, clinical determinants of HIV serostatus will be assessed. The outcome or 
the dependent variables will be HIV serostatus: HIV test result, ever tested HIV, ever 
tested AIDS). The quantitative approach will be used to quantify the behavioral and 
demographic determinants for testing statistically significant results.  I will conduct a 
multivariate analysis of variance (MANOVA). The quantitative method will further 
produce quantitative descriptive statistics on HIV serostatus from this demographic 
health survey data. 
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Acronyms 
Abstain, Be Faithful, Condomize (ABC) strategy: An HIV prevention strategy that 
combines abstaining from sexual intercourse, being faithful to a one sexual partner, and 
using a condom during sexual activities (Burman, Aphane, & Delobelle, 2015). 
Acquired immune deficiency syndrome (AIDS): HIV with an advanced stage of a 
compromised immune system leading to the manifestation of opportunistic infections 
(Centers for Disease Control and Prevention, 2015). 
Acquired drug resistance (ADR): the development of mutation due to the 
replication of the virus while on ART (Omooja et al., 2019).  
Antiretroviral therapy (ART): HIV medication used to prevent and treat the virus.  
Cluster of differentiation 4 (CD4): glycoprotein instituted on the surface of 
immune cells like T helper cells, monocytes, macrophages, and dendritic cells that has 
significant roles in T cell growth and host resistances at the time of the viral infections 
(Xueyan, Yanping, Jianfeng, & Jiying, 2018). 
Deoxynucleic acid (DNA): double-stranded (helix) with sets of nucleotides 
containing genetic (hereditary) material in almost all living organisms.  
Highly active antiretroviral therapy: A combination of antiretroviral treatments, 
aimed at both targeting various stages of the HIV replication cycle and maximizing 
suppression of the virus.  
HIV incidence: The number of new HIV infections in a specific time and 
population (Friis & Sellers, 2004).  
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HIV prevalence: The number of individuals living with HIV in a specific 
population at a particular time (Friis & Sellers, 2004).  
Human immunodeficiency virus (HIV): A virus that infects humans and leads to 
AIDS (Centers for Disease Control and Prevention, 2015). 
Ribonucleic acid (RNA): a single-stranded (helix) nucleic acid present in all  
living organisms and acts as a messenger to carry instructions from DNA and to 
synthesize  proteins  
Serodiscordance: Mixed HIV serostatus in a sexual relationship; that is, one of 
the partners is HIV positive and the other is HIV negative (Persson, 2013).  
Serostatus: The result of an HIV blood test, either positive (referred to as 
seropositive) or negative (seronegative). When a person has not taken an HIV blood test, 
they have unknown serostatus. 
Sexually transmitted infections: Infectious diseases transmitted through sexual 
activity.  
Sub-Saharan Africa: The region of Africa below the Sahara Desert composed of 
countries located in East Africa, Central Africa, South Africa, and West Africa (Merdad 
& Ali, 2018).  
Test and treat: An approach to HIV management in populations with an HIV 
epidemic, in which health workers test people for HIV and immediately start them on 
ART (regardless of their CD4 cell count; Rozhnova, van, Heijne, & Kretzschmar, 2016).  
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Assumptions 
In this study, I use secondary data from the 2009–2010 Demographic Health 
Survey conducted in Zambia and Nigeria. In selecting this data, I have made the 
following assumptions: (a) the data are accurate, (b) the survey designers selected the 
appropriate measures for the variables, (c) experienced personnel collected the data, (d) 
survey administrators used the participants’ native language, and (e) participants 
provided accurate data. For the current study, I have further assumed that the sample size 
of 1,441 women is sufficiently large and that the data accurately represent the population 
of Zambian women (because the survey administrators collected data from both urban 
and rural groups). 
Scope and Delimitations 
In this study, I analyze demographic health survey data collected in 2009 and 
2010 in Zambia and Nigeria. I explore the demographic, behavioral, and clinical 
determinants of HIV serostatus in two groups of Zambian women (1,441 women total): 
adolescents (ages 18–24 years) and adults (ages 25–49 years). 
Limitations 
There are several potential limitations to this study. First, due to cultural, 
normative, or religious pressures, participants may not have provided full or accurate data 
(particularly in the areas of HIV, family planning, current and past sexual practice, 
previous abortions, and attitudes toward and use of HIV services). Women may have also 
withheld information due to fear of stigma or sexual violence from a male partner. 
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Second, the generalizability of this study’s findings may be limited because 
Zambia has a diverse population, and it may have been challenging for survey 
administrators to collect data from all ethnic groups, particularly those that are isolated. 
The sample may not include equal numbers of women from urban and rural locations. 
Therefore, sampling, selection, and recall biases might be introduced at the time of the 
data collection. Third, because the current study is a cross-sectional study, data are only 
available from one particular point in time, as opposed to over an extended period.  
Significance 
This study will contribute possible prevention strategies that target the women 
population who are at elevated HIV risk and is assumed to have potential relevance in 
impacting a positive social change specifically for Zambian women and possibly for the 
Sub-Saharan women with similar settings. The category of variables for this study 
includes independent variables and dependent variables from a secondary data set 
“Survey of HIV Status and Fertility Preference in Sub-Saharan Africa 2009-2010 
(ICPSR 36718).”  The independent variables are demographic determinants (age, 
location, marital status), clinical determinants (use of HIV services GOV, use of HIV 
services clinic, and use of HIV services NGO), and behavioral determinants (condom 
use, sexual partners, and HIV self-perceived risk). The dependent variables are HIV test 
result, ever tested HIV, and ever tested for HIV/AIDS. At the individual level, younger 
women in urban areas have male sexual partners of higher ages who practice risky sexual 
behavior (alcohol before sex, unprotected heterosexual interaction). The practice of 
perilous male sexual partners was disproportionately impacting women in Zambia and 
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women in other Sub-Saharan countries (Maughan-Brown, Evans, & George, 2016). 
There is a trend of increased risk of HIV and other sexually transmitted diseases (STDs) 
during pregnancy. The incidence and prevalence of sexually transmitted infections (HIV, 
chlamydia, gonorrhea, and syphilis) have increased in pregnant women in Sub-Saharan 
African and the rest of the world with the higher burden of STD infection for women 
below 30 years old (Teasdale et al., 2018). At the racial level, the rate of HIV mortality 
for Black women was eight times compared to White women (Nesbeth, Kandala, Najeeb, 
Nazneen, & Murthy, 2018). At a global level, the unknown HIV status was reported to 
cause eight times more deaths for women compared to men, and future research was 
recommended for identification of individuals with a high risk of HIV acquisition and 
detect their status and confirm this finding (Platt et al., 2016). I assume this study will 
provide additional insight in understanding the combination of behavioral, demographic, 
and clinical factors in determining HIV serostatus for Zambian female adolescent (18-24 
years) and female adult (25-49 years) who are in an uncontrolled burden of HIV 
infection, continuous risk of HIV transmission, and a higher epidemic in era of 
diminishing trend of HIV in the rest of the world (Agbor, Etokidem, & Ugwa, 2017; 
Freeman et al., 2012; Goldberg & Short, 2016; Mojola, 2017). 
Summary 
This chapter provided an overview of the study and literature on HIV/AIDS in 
Zambian women. Chapter 2 includes a detailed review of the conceptual and empirical 
research on HIV/AIDS in Zambian women.  
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Chapter 2 
Introduction 
In this chapter, a review of the literature deals with behavioral, demographic, and 
clinical determinants of HIV serostatus in Zambian women. Two age groups participated 
in the demographic health survey; 18-24-year-old (adolescents) and 25-49-year-old 
(adult) Zambian women. The literature review was used to assess the association between 
behavioral, demographic, and clinical determinants of HIV serostatus. The literature 
review is sectioned into categories including the conceptual framework, HIV awareness 
of women, HIV in Sub-Saharan Africa, HIV epidemics in Zambia, HIV prevalence in 
Zambia, HIV prevalence in Zambian women, behavioral determinants of HIV serostatus, 
clinical determinants of HIV, demographic determinants of HIV, HIV serostatus, and 
types of HIV testing. 
Literature Search Strategy 
Secondary data for the previous dissertation topic, The Immunomodulatory Role 
of Vitamin D in HIV Infected African American Women, was researched. The efforts and 
requests, which lasted approximately four months, for the secondary data from database 
managing organizations, were not fruitful. During a dataset search in the Walden 
University databases, Center for Research Quality, under the search word “HIV,” a 
demographic health survey called the Survey of HIV Status and Fertility Preferences in 
Sub-Saharan Africa, 2009-2010 (ICPSR 36718) updated/released by Bankole Akinrinou 
was located. This prompted the development of a new topic on April 10, 2017. The 
survey was conducted in Zambia and was posted in the Inter-University Consortium for 
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Political and Social Research (ICPSR). The dataset was used to address the research 
questions under the topic, Behavioral, Demographic, and Clinical Determinants of HIV 
Status in Zambian Women. The keyword used to search this secondary data in Walden 
University’s “Center for Research Quality,” specifically in ICPSR datasets, was HIV. 
The literature sources for the current study were searched solely within the Walden 
University EBSCO search engine. The search keywords were HIV, HIV/AIDS, HIV 
Serostatus, HIV prevalence, HIV incidence, Global HIV prevalence, HIV prevalence, 
HIV incidence, and HIV epidemics, HIV in Sub-Saharan Africa, and HIV in Zambia, 
Women HIV awareness, and women HIV awareness in Sub-Saharan Africa. The search 
modes and expanders (Boolean/phrase, find all my search items, and find any of my 
search items) under the search options of the EBSCO search engine were pertinent 
mechanisms that provided tremendous possibilities and opportunities to obtain specific 
literature and diverse literature types that could be used for the various contents of the 
literature review. 
Conceptual Framework 
The World Health Organization’s Commission for Social Determinants of Health 
(CSDH) was the conceptual framework used in this study. The CSDH reviewed extensive 
evidence on the social determinants of health and addressed the behavioral and 
demographic factors that impact health equity and community health (Östlin et al., 2011). 
In the conceptual framework, population health was addressed, and an understanding of 
the community health inequalities at the global level, both in wealthy and developing 
countries, was provided (Venkatapuram, 2010). Moreover, the aforementioned 
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conceptual framework had been applied in low and middle-income countries and proved 
useful for measuring health inequalities and involving policymakers for health promotion 
of the population (Guerra, Borde, & De, 2016).  
In a cross-sectional sequential explanatory mixed-method design guided by the 
World Health Organization Commission Social Determinants of Health, the connection 
between men’s involvement with multiple sexual partners, and the extent to which 
women were at a higher risk of HIV infection were publicized at community and 
individual levels. In that study, in addition to men’s multiple partners, factors such as 
economic dependence, alcohol-drinking behaviors, and lack of financial certainty 
increased women’s risk of HIV (Mtenga, Pfeiffer, Tanner, Geubbels, & Merten, 2018). 
The authors conducted a literature review on the social determinants of HIV health in 
different social, economic, and demographic settings. The authors revealed that 
differences in gender, age, race, sexual behaviors (multiple sexual partners, sex worker, 
noncondom use), low literacy level, unemployment, and low economic status were risk 
factors for increased rates of HIV infection and HIV transmission (Saffier, Kawa, & 
Harling, 2017). Biomedical researchers dealt with this conceptual framework, which was 
used to find the causal agents of communicable diseases, control methods by biomedical 
researchers, identify the risks associated with chronic disease, and minimize the chances 
of chronic illnesses by epidemiologists (Masic, 2018). The World Health Organization’s 
Commission for Social Determinants of Health influenced the dynamic HIV/AIDS for 
demographic determinants (gender, age, social network) and behavioral determinants 
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(sexual partners, condom use) on the rate of HIV infection to people living with HIV 
(Araújo & Duarte, 2018). 
 
  
Figure 1. World Health Organization's Social Determinants of Health Conceptual 
Framework. 
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Figure 2. World Health Organization (2010) A conceptual framework for action on the 
social determinants of health. Geneva: World Health Organization; 2010. 
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Figure 3. Modified World Health Organization (2010). A conceptual framework for action on the social determinants of 
health. 
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22 
 
Overview of HIV 
The human immunodeficiency virus (HIV) is a retrovirus that infects humans and 
may cause AIDS if left untreated. The HIV-1 is a ribonucleic acid (RNA)-coated virus 
that lacks deoxynucleic acid (DNA) and is believed to be etiologically responsible for the 
development of active immunodeficiency syndrome(AIDS) (Trovato, D'Apice, Prisco, & 
De, 2018). The major types of HIV classification include HIV type-1 and HIV type-2, 
with differences in genetic features and viral antigens. On the other hand, the 
immunodeficiency virus has two categories: human (human immunodeficiency virus, 
HIV) and nonhuman origin (simian immunodeficiency virus, SIV).  
According to epidemiological and phylogenetic analyses, the origin of type-1 HIV 
was the Central African Chimpanzee, and the origin of type-2 HIV was the West African 
Sooty Mangabey (German Advisory Committee Blood Subgroup, 2016). The type-1 HIV 
(HIV-1) is globally more predominant, spreads at a faster rate, and varies in genetic 
structure and antigenicity, compared to type-2 HIV (HIV-2), which has limited 
distribution and a relatively low rate of progress (Júnior, Andrade, Ferreira, Oliveira, & 
Pinheiro, 2014). The transmission of HIV-1 from one partner to another mainly occurs 
via sexual activities, and from an HIV positive mother to her child during labor, delivery, 
and breastfeeding. HIV can also be acquired by a healthy person, from an infected 
person, through an injecting-needle exchange, and through occupational needle sticks 
blood exposure.  
The human immunodeficiency virus contains two ribonucleic acids(RNA) and  it 
acquires DNA through reverse transcription, which provides the opportunity to integrate, 
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assemble, and commence viral reproduction using the host cells as replication machinery. 
HIV mainly infects and destroys the cluster of differentiation 4 (CD4) immune cells, 60% 
of which are found in the gastrointestinal tract, and works by disrupting and dislocating 
the normal flora, progress into the stages of immunocompromising and succumbing the 
host to opportunistic infections (Williams-Orlando, 2017). The scale of HIV infection 
varies along gender lines, and in most situations, women are at a higher risk of acquiring 
the virus. Out of about 1 million HIV positive Zambians, 58% were women, indicating 
the level of vulnerability of females compared to males. The level of vulnerability was 
attributed to an uneven physiological risk in a heterosexual relationship and gender-
related violence experienced by women (Viljoen et al., 2017).  
The awareness of HIV serostatus has paramount importance in controlling new 
infections. In the United States, of 1.2 million people living with HIV, about 13% are not 
aware of their infection, which increases new infections, and weakens the public health 
efforts to slow down HIV prevalence (Wei, Mulatu, Rorie, Hui, & Gilford, 2017). There 
are three major types of HIV infections. Acute HIV infection (AHI) is characterized by 
the presence of viremia (the virus in the blood) in human blood, with the absence of 
specific HIV antibodies, and has a higher potential of infectiousness (Hino et al., 2018). 
In 2016, the mortality of approximately 35 million people from acquired 
immunodeficiency syndrome (AIDS)-associated calamities, and 36 million people living 
with HIV were reported (Word Health Organization, 2017). In an era of prevention and 
treatment advancements, HIV/AIDS remains a critical cause of death and suffering in the 
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SSA, accounting for 70% of worldwide emerging HIV infections and AIDS-related 
mortality and morbidity (Akinyemi, 2016).  
In the era of highly active antiretroviral therapy (HAART) use and the subsequent 
changing pattern of HIV transmission, the heterosexual transmission now accounts for 
greater than 70% of the new cases identified worldwide, with the higher number of HIV 
infections victims being women (Devadas et al., 2018). HIV initially attaches to the 
human cells and then multiplies using the CD4 machinery of replication, progressing 
throughout the body in a seven-stage life cycle process, which informs the target of 
therapeutic interventions to suppress the virus. The life cycle stages of HIV are binding 
(attachment), fusion, reverse transcription, integration, replication, assembly, and 
budding, which are the targets of action of HIV medications (Adamson & Freed, 2010; 
Chupradit et al., 2017; Lucera et al., 2017; Malik, Chauhan, Rath, Murthy, & Goyal, 
2017). 
Distribution of HIV 
HIV-1 and HIV-2 are the two main types of HIV. HIV-1 is more pathogenic than 
HIV-2, which is limited in distribution in West Africa (Williams-Orlando, 2017). It also 
has temporal and spatial distribution. The spatial distribution of HIV is a paradigm that 
deals with geographical distributions. The temporal distribution of HIV was assessed to 
understand factors that caused mortality, despite early commencement of antiretroviral 
therapy (ART), of HIV infected individuals in Nigeria, a Sub-Saharan African country 
with the highest burden of HIV infections (Akinyemi et al., 2015). Akinyemi (2016) 
found that the variations in the spatiotemporal distribution of HIV implied that the 
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direction of the focus of interventions should address high-risk communities and sections 
of society, to minimize new HIV acquisitions. The HIV prevention strategies were more 
effective with even distribution of HIV testing sites, including the increase in nonclinical 
tests and self-testing kits (Chen et al., 2017). Although the higher prevalence of HIV-2 is 
in West Africa and India, the report by Zbinden, Dürig, Shah, Böni, and Schüpbach 
(2016) demonstrated that the distribution of HIV-2 in the United States and Europe was 
due to migrations, and they recommended the consideration of diagnosis for coinfection 
of HIV-1 and HIV-2. 
HIV Serostatus 
Awareness of HIV serostatus provided the opportunity to start, link to, and adhere 
to antiretroviral medications. At a societal level, approximately 30% of new infections 
were attributed to unknown HIV serostatus persons infecting their sexual companions 
(Bradley, Vidot, Gaul, Sutton, & Pereyra, 2018). Based on Bradley and colleagues 
(2018), many public health practitioners highlighted the essentiality of HIV testing, 
specifically for communities that are excessively impacted by HIV. The National Institute 
of Health in South Africa suggested the “Seek, Test, Treat, and Retain” HIV prevention 
strategy for HIV serodiscordant couples (Doherty et al., 2016). Awareness of HIV 
serostatus has several public health benefits such as effective prevention, reduction of 
transmission, and managing epidemics. Authors in South Africa reported that about 24% 
of older adults living with HIV were untested and that efforts focused on self-reported 
HIV serostatus would lead to interventions, launching treatments, and taking prevention 
actions (Rohr et al., 2017).  
26 
 
HIV serostatus is classified into HIV positive, HIV negative, unknown serostatus, 
and mixed HIV serostatus. A mixed HIV serostatus in a couple relationship 
(serodiscordant couple) refers to one of the partners being HIV positive and the other 
being HIV negative (Bazzi, Leech, Biancarelli, Sullivan, & Drainoni, 2017). HIV 
positive refers to the acquisition of the retrovirus in blood, confirmed through serological 
tests, while the presence of the HIV antibody is an indicator of acquiring the virus in the 
body (Zemp, Johnson, & Bodenmann, 2019). An HIV negative serostatus confirms the 
absence of the virus in the blood post serological test, and HIV negativity informs to 
follow safety measures and practice prevention interventions to avoid new HIV infection 
and thereby control HIV pandemic (Mayaphi et al., 2018). Mixed serostatus is a 
condition where one partner is HIV positive, and the other partner is HIV negative within 
a couple’s relationship. Researchers presented a possible explanation for the existence of 
a mixed HIV serostatus also called HIV seroconcordant couples. For an HIV 
serodiscordant couple, intervention is required to protect HIV uninfected women and 
HIV infected men from HIV acquisition from their HIV positive partners, specifically at 
the time of conception and limit HIV vertical transmission (Joseph et al., 2018). The 
identification of HIV during acute HIV infection underlines positive serostatus, and the 
disclosure at this stage will have a profound advantage for the prevention of HIV 
transmission (Hino et al., 2018). There is an interconnected congruence of HIV 
incidence, prevalence, and epidemics, and HIV prediction serves to measure incidence 
from prevalence, prevalence from incidence, outbreaks from the occurrence, and 
prevalence (Saffier, Kawa, & Harling, 2017). 
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HIV Incidence 
HIV incidence varies with heterosexual partners, ages differences, occupation, 
demographics and population heterogeneity, and the state of risk associated with 
exposure to HIV infection. HIV incidence is the result of HIV seroconversion, discourse 
to the development of a detectable HIV antibody as a result of a response to HIV 
infection (Marty et al., 2018). Laeyendecker et al. (2018) reported that the 
implementation of advanced testing techniques was necessary to best estimate HIV 
incidence from HIV surveillance, and longitudinal cohorts depending on the availability 
of funds. The extent of risk factors was highly related to the incidence and the rise of HIV 
epidemics. Typically, injection drug users in the Middle East and North Africa showed 
elevated new epidemics and a higher prevalence of HIV (Mumtaz et al., 2018). Among 
the general population in sub-Saharan Africa, young women aged 15 to 24 years are at 
the highest risk of HIV infection, with 25% of new infections occurring among this group 
in 2015. Young women’s increased risk of HIV acquisition is due to a complex interplay 
of biological and behavioral factors (Acharya et al., 2018). 
Stages and Classification of HIV Infection 
CD4 cells are part of the immune system in the white blood cells, whose roles are 
to fight infections. The CD4 cell (CD4+) counts have a direct relationship with the viral 
load and CD4+ counts with a threshold of 350 cells/mm3 and initiate ART for new HIV 
infections (Govender et al., 2014). In contrast to the threshold of CD4 counts necessary to 
start HIV therapy, Yah (2017) advised providing treatments to HIV-infected individuals 
regardless of the CD4 counts, to advance prevention, and to reduce and control HIV-
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associated illness, deaths, and opportunistic infection. ART is believed to reduce the viral 
load and reconstructs the CD4+ T-cells. Researchers in Nigeria showed the failure of 
immune reconstruction to the CD4 of 500 cells/mm3 post taking ART for a year. Old age, 
comorbidity of infections with HIV, and development of immunological 
nonresponsiveness were the reasons for the failure of the immune revival (Motayo et al., 
2017; Udeh et al., 2019).  
HIV is categorized clinically and with regards to phases. The Center for Disease 
Control and Prevention (CDC) classified HIV infection into three clinical stages (A = 10, 
B = 16, and C = 8), which indicate the stages of disease development (Alvarez-Tostado, 
Inozemtseva, Aguiñiga, López, & Matute, 2016). The CD4+ count is considered the gold 
standard for measuring the advancement of HIV infection (Olusola et al., 2017). A study 
on the pre-AIDS stage of HIV infection indicated that HIV infection was defined by 
stable CD4+ T-cell counts, the viral load, and the length of the symptomless HIV 
infection (De Medeiros et al., 2016). HIV-1 has two phases of infection, acute and 
chronic, and stages during the development of the disease that causes the deterioration or 
reduction of the helper CD4+ cells, and the hyperactivation of the immune system 
(Gorenec et al., 2016). Depending on the signs and symptoms in HIV-infected 
individuals, HIV could be in the form of symptomatic, asymptomatic, and opportunistic 
infections (Gascón et al., 2018). Anto et al. (2018) recommended proteinuria, a urine test 
for monitoring HIV, for predicting the extent of HIV infection and the immediate use of 
HAART to increase CD4 counts for immune declined HIV infected people. 
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Types of HIV Tests 
The most common HIV test types are the HIV Antibody test, HIV 
Antibody/Antigen combination test, and the HIV Nucleic Acid RNA test (Masciotra et 
al., 2017; Stafylis & Klausner, 2017). The nucleic acid test identified the presence of HIV 
RNA in the early stages of HIV infection. Each of the HIV test types has characteristics 
in terms of sensitivity, specificity, and efficacy, to minimize false results and assure the 
quality and cost-effectiveness of the tests (Delaugerre et al., 2017). The combination of 
antibody and antigen (AB/AG) test is more efficient for the detection of primary HIV 
infection (Ghisetti, Coignard, Allice, & Thoai Duong, 2017). As Fransen et al. (2017) 
indicated, a combination of testing agents showed the efficacy of specificity and 
sensitivity of the test to identify acute HIV infection, which was challenging due to 
asymptomatic signs. For urban and semiurban settings of low- and middle-income 
countries, Moshoeu, Kuupiel, Gwala, and Mashamba-Thompson (2019) demonstrated the 
application of home-based HIV testing and counseling, to address clinical determinants 
associated with HIV testing in high epidemics settings. In Zambia, oral HIV tests are 
utilized to increase testing coverage (Chanda et al., 2017). There are barriers and 
facilitators of HIV testing in Zambia (Qiao, Zhang, Li, & Menon, 2018). Rapid antibody 
tests and advanced medicine and technologies that have shaped HIV testing are the 
facilitators of HIV testing. Barriers to HIV testing include stigma and discrimination. 
Qiao and colleagues (2018) further emphasized that improvements in HIV testing 
allowed  HIV status awareness and the beginning of cascades of treatment that preclude 
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HIV transmission, connection to HIV care, beginning of medication, sustaining to ART, 
and consequentially suppressing the virus in crucial communities.  
 Based on experimental evidence, universal testing and treating would progress 
HIV care and HIV prevention at community levels despite application at a broader scope 
(Perriat et al., 2018). HIV testing, concomitant with counseling at a community level in 
Zambia, was successful in teaching the sexual risk (behavioral determinant) for 
developing HIV awareness and strengthening HIV prevention and HIV care (Witzel, 
Lora, Lees, & Desmond, 2017). The preference of antigen/antibody tests was higher in 
effectiveness relative to the detection of an acute HIV infection and was able to reduce 
the risk of viral transmission and development of resistance. Although these tests were 
effective in the detection of acute infection, most primary infections can be 
asymptomatic; thus, retests were recommended after a month for any missed initial 
infection (Delaugerre et al., 2017). Peter et al. (2017) suggested that health professionals 
implement coordinated approaches, and familiarize themselves with a wide range of 
testing areas, with increased scalability and equitability to the HIV tests.  
In a wide-scale community HIV testing in Zambia, authors advised on the 
practice of the right HIV testing algorithm and rigorous training to maximize the testing 
performance at large scale (Bock et al., 2017). The authors encouraged future research to 
consider the individuals in the community in ART, who contributed to false-negative 
results after the implementation of HIV population-based HIV testing. 
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HIV Prevention Strategies 
The purpose of HIV prevention strategies is to reduce new infections, thereby 
precluding horizontal and vertical transmission, and improve the quality of the lives of 
people living with HIV/AIDS through HIV interventions, sexuality education programs, 
policies, and the implementation of evidence-based information (Anderson, Ghys, 
Ombam, & Hallett, 2017; Sharma, Barnabas, & Celum, 2017; Warren et al., 2018). A 
brief discussion of each of the HIV prevention strategies follows.  
Advocacy on HIV Disclosure  
Promoting open sexual communication is part of advocacy efforts to curb the 
spread of HIV. One of the advocacies relies on the implementation of voluntary medical 
male circumcision for reduction of HIV incidence (Sgaier et al., 2017). Biomedical HIV 
prevention deals with the practice of preventing the spread of HIV through vaccinations. 
Addressing infidelity, through teaching and counseling, in concurrent sexual partners was 
suggested as an effective HIV prevention strategy (Parker, Pettifor, Maman, Sibeko, & 
MacPhail, 2014). HIV prevention strategy targets the HIV serostatus of couples. For HIV 
discordant couples, prevention strategy depended on the concurrent actions of reducing 
risks and preserving the couple’s relationship (Ngure et al., 2016). HIV serostatus 
disclosure allows for treatment services and facilitates HIV testing for a sexual partner. 
Both serostatus disclosure and partner testing will contribute to the reduction of new HIV 
infections and to the ultimate goal of eliminating HIV (Adeniyi et al., 2017). Advocacy 
for the reduction in HIV risk improves social interaction, influences public health policy, 
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prevents overdoses, and eventually decreases HIV transmissions (Story, Kao, Currin, 
Brown, & Charles, 2018).  
Nutrition for People Living with HIV 
The efficacy of ART increases with nutrition that promotes health and helps 
maintain the immune system. Essential nutrition, such as vitamins, minerals, 
micronutrients, and vitamin D was extensively studied and recommended as an integral 
component of HIV prevention. Vitamin D has a traditional homeostatic role in calcium 
regulation, and most importantly, it immunomodulates the immune system and defends 
the body from infections that include HIV (Myszka & Klinger, 2014; Mastaglia et al., 
2017). Vitamin D deficiency increased the viral load and elevated inflammation with 
higher HIV related mortality and morbidity for Black Americans compared to White 
Americans; the severity of HIV was more pronounced for Black American women than 
White American women (Bobbitt et al., 2015; Coelho et al., 2015; Havers et al., 2014).  
Cultural Competency  
Perry-Mitchell and Davis-Maye (2017) stressed the use of evidence-based 
African-centered prevention that is culturally appropriate, to reduce disproportionate new 
infections and contain the fast spread of HIV in this community. Religion and culture 
possess taboos, metaphors, and understanding about HIV. The negative perceptions of 
people in Guinea Bissau, Africa, led to inadequate responses to HIV and succumbed the 
population to its spread, and increased mortality, and morbidity (Kelly-Hanku, Aggleton, 
& Shih, 2014; Shaw, McCrimmon, Mergenova, Sultangaliyeva, & El-Bassel, 2017). The 
integration of culturally relevant approaches proved beneficial for the promotion of HIV 
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prevention, addressing health behaviors at the individual, community, population, and 
policy levels (Wilson et al., 2016). From a holistic lens, the comprehensive consideration 
of the social determinants of health, and the design of strategies to use social capital, 
improve ART compliance, and address disparities (geographical, race/ethnic, gender, 
literacy level) will significantly reduce new HIV infections (Bayati, Feyzabadi, & 
Rashidian, 2017; Gonah & Mukwirimba, 2016; Jun-Fang et al., 2017; Perez-Brumer et 
al., 2017).  
ABC-Strategy (Abstain, Be-faithful, Condomize)  
The ABC-strategy promotes HIV-prevention factors such as abstaining, being 
faithful, and using condoms. The ABC-strategy was practiced in South Africa through 
advocacy and education showed success in turning the HIV epidemic into a manageable 
state (Burman, Aphane, & Delobelle, 2015). Eggers et al. (2017) advised implementing 
sexual abstinence interventions in conjunction with addressing HIV health awareness, 
understanding the ability to postpone sexual activities, and working on behavioral 
changes to drinking alcohol. Besides using an HIV prevention strategy, abstinence from 
sex was a suggestion as alternative protection of teenage pregnancy and other sexually 
transmitted infections (Mokwena & Morabe, 2016).  
The Test-and-Treat Strategy  
The test-and-treat strategy is the WHO’s guideline to initiate ART for HIV 
infections, post-diagnosis, to maximize HIV medication and limit subsequent spread 
(Rozhnova, Van, Heijne, & Kretzschmar, 2016). The ART will be initiated instantly, 
irrespective of the number of CD4+ T-cells, in accordance with the Universal-Test-and-
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Treat WHO strategy. Kabogo, Muniu, Wamunyokoli, Musoke, and Songok (2018) 
recommended UTT to Africa by developing a new strategy to improve medication 
compliance with children and youth. Similarly, the strategy of seek, test, treat, and retain 
(STTR) will be more conclusive in reducing HIV morbidity and mortality. The STTR 
strategy could be used for the general population, and specifically for prisoners (high-risk 
population), to improve testing, advance medication adherence, and maintain a 
connection to caring services during incarceration, and after release to society from 
imprisonment (Golin et al., 2016; Normand, Montaner, Chi-Tai, Zunyou, & Yi-Ming, 
2013).  
HIV Surveillance  
The purpose of HIV surveillance varies across countries and settings. The primary 
purpose of HIV surveillance in the USA changed from the monitoring of HIV epidemics 
and the people affected, into assessing the impact of integrating HIV surveillance and 
field activities and connecting to healthcare providers (Hood et al., 2017; Beltrami, 
Dubose, Carson, & Cleveland, 2018). HIV surveillance was conducted in the USA based 
on algorithms categorized into a traditional algorithm (initial HIV antibody immunoassay 
followed by a Western blot or immunofluorescence antibody test), recommended 
algorithm (initial HIV antibody followed by HIV-1/2 type-differentiating antibody test), 
and rapid algorithm (rapid tests on the same date). The rapid diagnostic HIV test 
algorithm increased the number of people diagnosed, whereas the combination of 
traditional algorithm and the recommended test algorithms connected more HIV infected 
people with HIV care services than the traditional algorithm alone (Peruski, Dong, & 
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Selik, 2018). The HIV-1/2 antibody test was a procedure to detect concomitant infection 
type-1 HIV and type-2 (HIV-1 and HIV-2) in serological tests (Luo et al., 2019).  
An adverse effect active surveillance system was used to monitor the Perspex 
male circumcision device in seven African countries, and such programs could increase 
its acceptability when supported with passive surveillance through an electronic 
information delivery system (Adamson, Tafuma, Davis, Xaba, & Herman-Roloff, 2017). 
Schwartz et al. (2017) reported, specifically for disproportionately high HIV-burden 
regions, the need to use a routine viral load monitoring tool to increase treatment efficacy 
and interoperable the surveillance data for facilitating the exchange of valid information 
in the healthcare institutions. A study conducted in six Sub-Saharan African countries 
identified gaps in HIV treatment distribution and delivery strategies, and HIV diagnosis 
policies to ensure continuity of health care for people living with HIV were 
recommended (Church et al., 2017). Likewise, a global study by UNAIDS focused on the 
maximization of antiretroviral drug distribution and increasing HIV testing, to understand 
the viral load and determine HIV therapy efficacy to meet the 90-90-90 therapy 
objectives for 2020 (Inzaule et al., 2016). Moreover, Buthelezi, Davidson, and Kharsany 
(2016) emphasized fast-track HIV surveillance data collection on incidence and 
prevalence, for resource-limited to understand obstacles, the pattern of spread, and 
forecast new HIV infections.  
Biomedical HIV Prevention  
Biomedical HIV prevention intervention includes the use of a condom, treatment, 
antiretroviral therapy, and male circumcision to reduce the risk of HIV transmission. HIV 
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treatment options include anti-HIV medications taken pre-and post-exposure, and ART 
taken after HIV infection occurs. HIV negative individuals use Pre-exposure prophylaxis 
(PrEP) to prevent HIV infection, and post-exposure prophylaxis (PEP) for individuals 
who have the probability of HIV exposure or are indeed exposed to HIV positive 
individuals, to deter HIV transmission (DiStefano & Takeda, 2017). The use of vaccines 
is ongoing in trials with a prospective promise to be part of the biomedical HIV 
prevention strategy. The efficacy of biomedical HIV preventions is maximized when 
used with the combination of a standardized testing for sexually transmitted infection, 
consistent treatment, use of counseling, and consistent compliance with all prevention 
strategies (Herbeck et al., 2018). In summary, the biomedical HIV prevention strategy 
involves the use of condoms, vaccines, ART, PrEP, and PEP for HIV negative 
individuals, microbicides, male circumcision, and management of STIs.  
Herbal Inhibition of HIV  
Bunluepuech, Tewtrakul, and WattanapiromsakuL (2016) claimed the first report 
on the screening of Thai plants to test the inhibitory behavior on HIV-1 protease and 
provided a suggestion for further study of HIV/AIDS treatments. These researchers 
reported that one of the 29 cotton extracts, C. gerrettiana, had the highest potential in 
inhibiting HIV-1 protease activities. In a similar study, Áy, Hunyadi, Mezei, Minárovits, 
and Hohmann (2019) observed that the herbal medication herbacitrin, extracted from 
cotton, had inhibited both the HIV-1 reverse transcriptase and integrase and further 
suggested that herbacitrin had probable efficacy to interfere with the life cycle of HIV at 
various stages.  
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Eradication of HIV  
The suppression of the HIV-1 by antiretroviral drug therapy enables the 
establishment of a latent HIV reservoir in the resting CD4 cell memory. Following the 
aforementioned, HIV is neither targeted by ART nor detected by the immune system, 
hiding without apparent causes of damages. However, the Cessation of ART allows the 
regrowth and replication of the provirus (HIV-DNA in the reservoir), and the regrowth of 
new HIV will not be an easy target with ART in the reservoir (Fryer, Wolinsky, & 
McLean, 2018). The goal of HIV eradication evolves from overcoming the challenge of 
eliminating the virus that hides in reservoirs. Researchers are optimistic about the 
elimination of HIV and recognize the cascades of challenges and barriers to realizing 
such a breakthrough achievement. Viral latency is one of the most challenging in 
quantifying latency reversal and depletes the reservoir of provirus that would have the 
potential to resume infection under favorable pathogenic conditions (Spivak & Planelles, 
2016). Bashiri, Rezaei, Nasi, and Cossarizza (2018) described sterilizing cure (stem cell 
transplant, genome edit, gene therapy) and functional cure (suppressing the viral load and 
boosting CD4 counts), whereas Pankrac, Klein, and Mann (2017) used therapeutic 
vaccinations to eradicate HIV. In both cases reversing the latency period provirus (HIV 
DNA) into detectable levels and eliminating the virus by the “shock and kill” strategy 
was used; “shock” refers to initiating the resting provirus into transcriptional form and 
making it detectable, and “kill” refers to eradicating the virus with therapeutic means or 
immune system.  
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Herbal medications are potential complements to ART in reducing drug resistance 
and performing a probiotics’ role. According to an author’s description, the herbs and 
medicinal plants are probiotics that increase the number of CD4 cells and initiate the 
activity of natural killer cells. The increase in the activity of killer cells during pathogenic 
invasion and attacks, deprives the virus of its replicating abilities, becoming an efficient 
means to wipe out the pathogens (Williams-Orlando, 2017). Xu et al. (2017) published 
about a German HIV-infected patient and the success in eradicating HIV in this patient 
through stem cell transplant and the development of mutant cells resistant to HIV 
infection after eight years. The success in the German patient signified a cure to HIV. In 
short, reversing the latency and clearing the provirus could be a target to eradicate HIV 
through the combination of ART, therapies, and prevention strategies (Margolis, Garcia, 
Hazuda, & Haynes, 2016). Drug resistance developed from non-compliance of HIV 
medications, and the use of low dosage medications adds another level of challenge to 
eradicating HIV.  
The acquired drug resistance (ADR) HIV somewhat complicates the efforts to 
suppress the virus and reduce transmission. When the ADR virus transmits to ART naïve 
persons, it forms a transmitted drug resistance (De Luca & Zazzi, 2015). Dubé et al. 
(2018) warned to avoid unrealistic promises for the worldwide elimination of HIV and 
they instead advised a focus on suppressing HIV to sustainable levels for the millions of 
people living with HIV/AIDS. Derivatives of natural products were used as a “shock and 
kill” strategy to target HIV reservoirs, reactivate the latent HIV DNA, and kill them with 
the immune system or anti-HIV drugs. To date, such approaches have been unsuccessful 
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in consistently eliminating the reactivated latent HIV DNA (Andersen, Ntie-Kang, & 
Tietjen, 2018).  
The derivatives of natural products are types of latency reversal agents. Maraviroc 
serves as an antiviral latency-reversing agent, and subsequent interventions are required 
for eradication of HIV-1, post activation of the viruses in the latency reservoir (Madrid-
Elena et al., 2018). When the HIV DNA is in the latency period, the immune system does 
not recognize the virus, and there is no effect of the anti-viral drugs; consequently, 
latency reversal agents are needed to implement the “shock and kill” strategy. Antibodies 
are considered candidates for the eradication of HIV in HIV research. The administration 
of antibodies is being used as an immunotherapeutic approach to eradicating HIV (Mujib 
et al., 2017). This immunotherapeutic approach shows an eradication of the HIV infected 
cells in vitro, and facilitates the development of a combination of antibodies for the 
prospective effective elimination of HIV infected immune cells and the viral reservoir.  
The Algorithm of HIV Prevention  
The World Health Organization used the algorithm of HIV prevention for 
screening, diagnosis, treatment of HIV, and prevention of HIV transmission. The WHO 
recommended the validation of the HIV-1 testing algorithm for applying rapid diagnostic 
tests tailored to each country, and retesting HIV-1 positive results before starting ART to 
reliably assure quality in Sub-Saharan Africa (Kravitz et al., 2018). There were several 
available HIV prevention algorithms. “Simple risk score algorithms” were reliable means 
to detect individuals with extended high viremia in Sub-Saharan Africa (Powers et al., 
2018). Harbertson et al. (2017) suggested increasing the specificity and sensitivity of a 
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rapid diagnostic test, to resolve the causes of the HIV positive diagnosis properly, and 
save costs in resource-constrained countries. HIV point-of-care testing (HIV-POCT) at 
non-facility-based community settings should follow the correct testing algorithm to 
ascertain quality assurance. In HIV-POCT, quality assurance can be proved possible by 
conducting rigorous training and supervisions to maximize sensitivity (Bock et al., 2017). 
The rapid diagnostic test does not always show high sensitivity and correct identification 
of HIV serostatus.  
Kufa et al. (2017) determined that random diagnostic tests had low sensitivity, 
high false negatives, and few false positives in a community setting HIV testing. They 
associated false negatives with new infections and the initiation of ART. The result of the 
HIV diagnosis algorithm requires a confirmatory algorithm to ascertain the HIV 
serostatus of the tested individuals (Kufa et al., 2017). A confirmatory HIV diagnosis 
rules out the false-negative and false-positive results and determines the appropriate HIV 
serostatus. The source of false-negative results can be due to misclassification of results 
and the inability to detect early infections.  
HIV diagnosis algorithms that assure quality testing are essential in linking HIV-
infected individuals to treatment, and for strategizing prevention interventions. According 
to Johnson et al. (2017), who corroborated the HIV diagnosis algorithm, HIV testing 
strategy and retesting practices will prevent false results (false negative or false positive) 
that could occur due to testing mistakes and new testing procedures. The HIV test 
algorithm, which applied rapid diagnostic tests, was recommended for Sub-Saharan 
Africa and other resource-limited areas that lacked laboratory facilities, infrastructure, 
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and a trained workforce capable of using advanced diagnostic techniques such as 
immunoassays and immunoblots (Kosack et al., 2017). False HIV results impair 
prevention efforts, erode the trust of HIV testing centers, and harm individuals who were 
misled regarding their serostatus. At the community level, false HIV positive results and 
the initiation of anti-drug therapy endanger public health through unnecessary 
administration of medication, facilitating an increase of the viral load, and accelerating 
horizontal and/or vertical transmission (Johnson et al., 2017; Kosack et al., 2017; Bock et 
al., 2017).  
Modeling and Simulation in HIV Prevention  
Modeling and simulation is an approach to strategize based on scientific evidence 
for practical measures that drastically reduce HIV transmissions (Jacobsen & Walensky, 
2016). The reduction of HIV transmission targets fundamental thresholds of intervention 
that consider global HIV treatments and cost-effective standards. A dynamic complex 
network determined a close similarity between the simulation and actual registry of new 
HIV incidents, implying the aspects of HIV expansion is a reason to teach male 
circumcision for HIV prevention in the Sub-Saharan Africa medication scenario 
(Campain et al., 2017). A simulated study on condom use helped to reduce new 
infections in HIV serodiscordant couples, and couples with unknown HIV serostatus 
(Monteiro et al., 2016). Researchers showed feasible modeling would be made using a 
geographic information system (GIS) simulation to predict HIV distribution effectively, 
and emphasized the need to conduct future research that outlines epidemics parameters 
(Shu et al., 2017).  
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Moreover, computer simulation modeling was a highly efficient tool for making 
public health and policy decisions (Shu et al., 2017). Computer simulation modeling 
allows assessing multilevel prevention interventions at downstream and upstream 
structures and minimizing costs. Minimization of costs could scale up prevention services 
in low- and medium resource countries. Anderson, Ghys, Omba, and Hallett (2017) 
strongly supported modeling tools that prioritized the geographical allocation of 
prevention interventions. This geographic allocation should augment the number of 
people living with HIV/AIDS (PLWHA), the patterns of HIV transmission among target 
populations, the specific choice of intervention tailored to the community and location, as 
indicators to strategize prevention interventions. 
Behavioral Determinants of HIV Serostatus 
Madiba and Ngwenya (2017) suggested the presence of increased HIV acquisition 
in women is due to the negative influence of male dominance leading to unsafe sexual 
practices. Mobility in the rural East Sub-Saharan African countries is pronounced with 
higher HIV sexual risk to women compared to men, associated with the exposure of 
unsafe sexual practices, induced by sexual violence and forced sex (Camlin et al., 2018). 
In Zambia and other Sub-Saharan African countries, adolescent HIV positive women 
who were with/without HIV medication were more prone to conceive children than 
adolescent HIV negative women, and an opposite trend was noted for women over 35 
years old (Marston, Zaba, & Eaton, 2018). The increase in the number of sexual partners 
created pressure in living conditions of families and harmful effects in contracting HIV 
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and other sexually transmitted infections for a large percentage of adolescent women 
living with HIV in sub-Saharan Africa (Zgambo, Kalembo, & Mbakaya, 2018).  
Condom use had several barriers in Sub-Saharan Africa. The availability of 
condoms, the consistent use of condoms, the types of condoms (efficacy of the condom), 
the cost of condoms, male willingness to pay for condoms, and the need to engage in HIV 
medication while using condoms were in strong association with women exposure to HIV 
infections (Nehl, Elifson, DePadilla, & Sterk, 2016; Evans et al., 2019). As reported by 
Zhang, Jemmott, and Heeren (2017), even though improvement in communication 
contributed to the ease of condom use and reduced sexual partners’ instability in couple 
relations. Furthermore, the determination of fertility preferences was a challenging 
decision in Zambian women and the other Sub-Saharan Africa women. The current data 
were inadequate in determining the fertility preferences of HIV infected Zambian women 
to better understand the trend of HIV epidemics (Yeatman et al., 2016). 
Demographic Determinants of HIV Serostatus 
Shisana et al. (2016) suggested having a focus on unmarried populations to 
advocate for HIV prevention. The unmarried individuals had shown low social coherence 
and unstable sexual partnering that would increase the risk of HIV transmission. The HIV 
risk had an increased rate for unmarried individuals, especially people with low 
socioeconomic status and low literacy levels. In Sub-Saharan Africa, the study on gender 
inequality has shown an HIV prevalence disparity between females and males (Sia et al., 
2016). In most of the SSA countries under this study, discrepancies in age, marriage 
situation, and careers contributed to higher HIV prevalence for females compared to 
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males. Besides, the relationship between jobs and education status, and the site of the 
HIV testing, impacted the effectiveness of volunteer counseling and testing efforts 
(Bibiana, Emmanuel, Amos, Ramsey, & Idris, 2018); whereas inadequate understanding 
of HIV became an obstacle to HIV testing and HIV serostatus cognizance (Nabukenya & 
Matovu, 2018). The demographic determinants (age difference between women and men 
and marital status) contributed to differences in HIV prevalence and the associated sexual 
risks to HIV infections between women and men (Sia et al., 2016). Knowledge of HIV 
serostatus was found critical for married couples to facilitate joint education and the 
prevention of HIV in marital relations (Musheke, Merten, & Bond, 2016). 
Clinical Determinants of HIV Serostatus 
Pilgram et al. (2018) noted an emphasis on the benefits of avoiding the negative 
perceptions of healthcare professionals by providing training on the potential use of pre-
exposure prophylaxis (PrEP) for preventing new HIV infection, and the need and 
colleagues for improving the PrEP delivery system in adolescent and adult women. 
Pilgram et al. (2018) also advised taking clinical steps of increasing PrEP accessibility 
and healthcare delivery to prevent the community from horizontal and vertical HIV 
transmission. The initiation of anti-HIV drugs (PrEP) for naïve ART persons had shown a 
significant role in reducing the acquisition of HIV infections (Pilgrim et al., 2018), and 
the use of PrEP had shown increased recipients among the adult population with durable 
acting PrEP medications (Krogstad et al., 2018). Besides, Masters et al. (2016) revealed 
that the promotion of HIV self-testing to pregnant and postnatal women might warrant 
cognizance of HIV status to men, and could maximize couple HIV self-testing. The use 
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of HIV services is one of the indications of HIV medication compliance. Part of the HIV 
infected individuals at community clinics in Sub-Saharan Africa discontinued their 
medications for unknown reasons (Asiimwe, Kanyesigye, Bwana, Okello, & Muyindike, 
2016). The cessation of HIV medications could jeopardize the health of HIV-infected 
individuals and might result in HIV transmission to the community. 
Behavioral, Demographic, and Clinical Determinants of HIV Serostatus 
Authors stated that demographic and behavioral factors predicted HIV, ethnicity, 
sexual partners, and sexual partners’ behaviors were tested in the prediction model used 
for improving electronic health archives (Dube, Marshall, Ryan, & Omonijo, 2018). 
Adeniyi et al. (2017) reported a significant association between adolescents (18-24), and 
HIV serostatus that include demographic (age, gender, employment, education, marital 
status, location), behavioral (attitude towards sexual partner, HIV disclosure), and clinical 
(ART adherence) determinants of HIV serostatus disclosure. Youth who had multiple sex 
partners and persons with drinking behaviors were more likely to non-disclose HIV status 
in their sexual relationships. Sexual acts, marital status, and HIV care services were risk 
factors for adolescent Zambians to the spread of vertical and horizontal HIV infections 
(Okawa et al., 2018). A lack of guarantee in food security played a role in the increase of 
HIV risk and susceptibility to HIV-infected women (53% of the study participants) 
younger than 24, with education levels lower than high school (Nyirenda, 2018). The rate 
of HIV varied with gender, age, and race (demographic determinants), while sexual 
relations with multiple partners and sexual practices of not using condoms amplified the 
rate of HIV infection; macro-determinants of HIV signaled an impact in the spread of the 
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HIV epidemics (Araújo & Duarte, 2018). As opposed to Araújo and Duarte (2018), 
Agbor, Etokidem, and Ugwa (2017) reported a high prediction of HIV serostatus 
disclosure with the association of ages, marriage status, and locations.  
Social factors, such as education, wealth, and media exposure, determined the 
level of knowledge and awareness and affected the behavior of women regarding STDs 
and HIV/AIDS (Rana, 2016). The promotion of health education was suggested to 
increase HIV awareness and reduce the erroneous perceptions of HIV as being a curse 
that is limited to Africa (Tecle & Andrasik, 2015; Zainiddinov & Habibov, 2016). The 
increase in general literacy levels and higher HIV health literacy was a demographic 
determinant that improved HIV awareness. Vanamail, Sehgal, and Kriplani (2014), and 
Vieira et al. (2017) concluded that education level was a critical demographic 
determinant for the prevention of mother to child transmission for people living with 
HIV. As a result of a qualitative study in Zambia, Musheke, Merten, and Bond (2016) 
noted that addressing the differences in gender power dynamics and improving couple’s 
HIV test centers could guarantee the development of shared awareness and acceptance, 
and management of the HIV serostatus within heterosexual relations. 
HIV in Sub-Saharan Africa 
The lack of a contemporary HIV testing algorithm for the identification of an 
acute HIV infection with the absence of specific HIV antibodies is a potential risk to 
resource-limited regions of the world, including Sub-Saharan Africa. Public health 
practitioners require timely diagnosis that confirm the presence of HIV at the earliest 
stage, and design treatments and preventions to reduce the spread of the virus, disrupt the 
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chain of infection, and promote HIV health in communities of resource-limited regions 
(Hino et al., 2018). In Zambia, HIV acquisition in a heterosexual HIV serodiscordant 
couple is risky for both men and women who are HIV negative, and the level of risk 
increases for women (Joseph Davey et al., 2018). Bazzi, Leech, Biancarelli, Sullivan, and 
Drainoni (2017) inferred the use of pre-exposure prophylaxis (PrEP) for HIV uninfected 
women in the USA who have couples an HIV serodiscordant men (an HIV infected man 
to secure safe conception and prevent horizontal and vertical transmission of HIV. The 
differential power dynamics in a heterosexual relationship in most of Sub-Saharan Africa 
disproportionately burdened women with HIV risk associated with intimate partners’ 
violence (Pulerwitz, Mathur, & Woznica, 2018).  
Sub-Saharan Africa is a region with the highest burden of HIV. In 2013, of 3.2 
million children who were living with HIV, the majority was from Sub-Sahara Africa. 
The routes of HIV transmission were from mothers to their children through prenatal, 
delivery, labor, and breastfeeding practices (Tadesse, Foster, & Berhan, 2015). Despite 
the disproportionate burden of HIV, Sub-Saharan Africa uses rapid HIV tests, which have 
no specificity for early detection, and provide false negative results to potentially 
infectious persons. The limitation to rapid HIV tests is due to low cost, and the use of 
HIV tests with high specificity and sensitivity was not possible due to the price and low 
availability in Sub-Saharan Africa (Mayaphi et al., 2016). 
HIV in Zambia 
The prevalence of HIV/AIDS in Zambia was much higher in adolescent girls (15-
19) due to associated factors such as stigma, shamefulness, religion, culture, negative 
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social media messaging, and conditions of infections (Mackworth‐Young et al., 2017). 
The HIV prevalence for persons 15-64 years rated at 12.3%, 10.6%, and 14.6% in 
Zambia, Malawi, and Zimbabwe, respectively. As part of the prevention program, global 
and timely HIV therapy was recommended for those infected, those aware of their status, 
and those who disclosed their status (Mwenge et al., 2017). Stigma and discrimination, 
including healthcare provider stigma, were a particularly salient barrier. Improving 
knowledge, social support, and acknowledgment of FSWs and women’s role in society 
emerged as facilitators to testing. Interventions to improve HIV testing among FSWs in 
Zambia will need to address barriers and facilitators at multiple levels, to be maximally 
effective (Chanda et al., 2017). Zambian women, 10-14 years in Sub-Saharan Africa were 
in amplified exposure to new HIV acquisition. The low general education level, lack of 
sexual education, and cultural barriers in having parent-daughter conversations on the 
risk of HIV contributed to the continuation of new HIV infections (Butts et al., 2018).  
HIV prevalence was 9.8% in urban Zambia compared to the rural communities 
where the prevalence is 5.0%; there existed a double risk in urban inhabitants than their 
rural counterparts (Chanda-Kapata et al., 2016). In communities with higher HIV 
prevalence, male circumcision helped reduce the rate of infection and minimized the cost 
of HIV prevention (Awad et al., 2015). The general trend in Sub-Saharan Africa was an 
increase in the rates of new HIV infections in adolescent women, which was attributed to 
the association of biological and behavioral determinants. The use of condoms was one of 
the prevention methods to reduce the risk of biological and behavioral determinants to 
new HIV infections (Acharya et al., 2018). Hegdahl, Fylkesnes, and Sandøy (2016) stated 
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that the constant vulnerability of women to HIV compared to men could indicate the roles 
of physiological characteristics in Zambia and other Sub-Saharan African countries. 
Besides, there was an increase in the prevalence ratio of HIV in younger Zambian women 
compared to younger Zambian men (Hegdahl, Fylkesnes, & Sandøy, 2016), and the 
overall trend implied 25% of new HIV acquisition occurred through individuals other 
than sexual partners (Kamali et al., 2015). 
Summary and Conclusions  
In Chapter 2, the World Health Organization’s Commission for Social 
Determinants of Health assessed the disproportionate HIV burden in Zambian women 
related to gender, age, disparities with male partners, and unsafe sexual behaviors. The 
different types of HIV serostatus (HIV positive serostatus, HIV negative serostatus, 
unknown HIV serostatus) indicated an association with the risk of HIV infection, rates of 
mortality, and rates of morbidity with other sexually transmitted diseases (Moodley, 
2017).  
The association of HIV serostatus (HIV positive serostatus, HIV negative 
serostatus, unknown HIV serostatus) with behavioral determinants was reviewed. 
Scholars of HIV, in systematic reviews, indicated the importance of demographic 
determinants such as age and education, HIV serostatus awareness, and the level of risk 
to HIV transmission because of non-condom use. Previous studies lacked conclusive 
findings on the levels of association of HIV serostatus with key demographic 
determinants (age, location, gender). Systematic reviews also recommended additional 
study-linkage to treatment and the commencement of antiretroviral therapy. The findings 
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in this study aim to contribute to the literature, with inferences on the data that can be 
generalized to Zambian women (adolescent women ages 18 to 24 and adult women from 
ages 25 to 49). In Chapter 3, the methodology and analysis of the present study are 
discussed.  
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Chapter 3 
Introduction 
This study assessed the association between demographic, behavioral, and clinical 
determinants of HIV serostatus for Zambian adolescent women (18–24 years) and 
Zambian adult women (25–49 years). The purpose of this study was to minimize the HIV 
epidemic among Zambian women, recommend possible measures to reduce new HIV 
infections and to promote the quality of life of Zambian women living with HIV/AIDS. 
The research strategy involved comprehending the association of key behavioral, 
demographic, and clinical determinants of HIV serostatus to affect positive social change 
among Zambian women and to draw possible generalizations to women with similar 
settings in the other Sub-Saharan African countries. In what follows, I included a 
description of the secondary data analysis used in the study’s research design and 
rationale. Following the research design and rationale section, I provided a brief 
description of the research methodology, which contains the study population, sampling 
and sampling procedures, and instrumentation and operationalization of constructs. 
Finally, I presented the data analysis information, ethical procedures, chapter summary, 
and transition to Chapter 4. 
Research Design and Rationale 
This dissertation research is an inferential study. The quantitative analysis would 
apply to secondary data from a demographic health survey. The research used the sample 
of women of 18 to 49 years old; the findings offered generalizations about the general 
population of Zambian women and possibly about communities in the other Sub-Saharan 
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African countries with similar settings. The independent variables were demographic 
factors (age, location, language, education, religion, and marital status), clinical factors 
(use of HIV services and attitudes toward use of HIV services), and behavioral factors 
(sexual activity; sexual partners; condom use; fertility preferences; attitudes toward and 
knowledge about HIV). The dependent variables were HIV serostatus and ever tested for 
HIV/AIDS. A cross-sectional survey design assessed the association between the 
independent variables and the dependent variables since the demographic survey data 
were collected at one point in time. A cross-sectional design is appropriate for the 
research questions focused on the association of independent variables with dependent 
variables from data collected by an on-site questionnaire for generalizing from a sample 
to a population (Cresswell, 2014).  
In a technological era where archived data sets are abundantly available by 
downloading various publicly available databases and other resources through formal 
requests, a secondary data analysis saves time and it is cost-effective (Tripathy, 2013). 
Methodology 
The researcher used a quantitative method to conduct the study. 
Population  
The study population included Zambian women 18 to 49 years old who were 
permanent residents in 8 provinces. The target population was from a demographic health 
survey conducted between 2009 and 2010. The demographic health survey contained 
1,4441 responses from Zambian women aged 18 to 49 years old about issues of fertility 
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preferences; HIV status; fertility preferences; attitudes toward and knowledge about HIV, 
and attitudes toward and use of HIV services (Bankole, 2017). 
Sampling and Sampling Procedures 
The sampling strategy divided each of the nine Zambian provinces Zambia into 
enumerative equal areas, based on the 2000 Zambian population and housing census. All 
households had the chance to be selected as part of the Zambian Demographic Health 
Survey (ZDHS) sample. The sampling procedure stratified the ZDHS sample into urban 
and rural areas. There were 18 sampling strata from the nine provinces. The samplers 
selected the EAs (enumeration areas) independently for all stratifications, beginning with 
the Census Supervisory Area (CSA) level and moving to the EA level. The sampling 
frame included Zambian women age 18 to 49 years old. The sampling frame excluded 
females younger than 18 years old, women older than 49 years old, and all males of any 
age.  
The research sample was sub-sampled from the 2007 Zambia Demographic and 
Health Survey (ZDHS). The sample was designed to provide specific indicators, 
including reproductive health indicators and HIV prevalence for each of the nine 
provinces in Zambia. Sorting the sample frame followed an implicit stratification and 
proportional allocation based on the geographical/administrative order and by using a 
probability proportional to size. Stratification sampling was completed before the 
selection of the sample (Croswell 2014). 
Specific procedures guided the sample selection. Households were listed from 
319 EAs. From each EA, an average of 25 households was selected through equal 
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probability systematic sampling. Out of the average total of those EAs, the ones in 
Northern province and Lusaka province were sub-sampled that shall be used for this 
study. I used a power analysis to determine sample size. The power analysis to determine 
the sample size included the justification for the effect size, alpha level, the power level, 
and the citation of the source for calculating the sample size. 
Using Archival Data  
This study used archival data from the Walden University website. The data 
source for this study was the Inter-University Consortium for Political and Social 
Research (ICPSR) Datasets. The ICPSR datasets were accessed through Walden 
University under Research and Quality for Research. Regarding the Instrumentation and 
Operationalization of Constructs, an on-site questionnaire was the basic data collection of 
the ZDHS. The operationalization of the ZDHS data indicated the unweighted data but in 
the form of a weight variable (WGT) which was used directly in the study analysis. The 
scores represented numeric values for the independent variables (behavioral, 
demographic, and clinical determinants of HIV serostatus). There was no available 
operational definition for each of the variables. The on-site questionnaire was a vital 
instrument used for these survey data. I plan to use SPSS statistics 25 software for the 
data analyses. The study dataset indicated the availability of the data suitable for analyses 
in SPSS format. The restated research questions and the hypotheses are presented in the 
next section. 
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Research Questions and Hypothesis  
Research Question 1: What is the association between behavioral determinants 
and HIV serostatus of Zambian female adolescents from ages 18 to 24 years?  
Ho1: There is no statistically significant association between behavioral 
determinants and HIV serostatus of Zambian female adolescents from ages 18 to 24 
years.   
Ha1: There is a statistically significant association between behavioral 
determinants and HIV serostatus of Zambian female adolescents from ages 18 to 24 
years.  
Research Question 2: What is the association between behavioral determinants 
and HIV serostatus of Zambian female adults from age 25 to 49 years?  
Ho2: There is no statistically significant association between behavioral 
determinants and HIV serostatus of Zambian female adults from ages 25 to 49 years. 
Ha2: There is a statistically significant association between behavioral 
determinants and HIV serostatus of Zambian female adults from ages 25 to 49 years.  
Research Question 3: What is the association between demographic determinants 
and HIV serostatus of Zambian female adolescents from ages 18 to 24 years?  
Ho3: There is no statistically significant association between demographic 
determinants and HIV serostatus of Zambian female adolescents from ages 18 to 24 
years.   
Ha3: There is a statistically significant association between 
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demographic determinants and HIV serostatus of Zambian female adolescents from ages 
18 to 24 years.  
Research Question 4: What is the association between demographic determinants 
and HIV serostatus of Zambian female adults from ages 25 to 49 years?  
Ho4: There is no statistically significant association between demographic 
determinants and HIV serostatus of Zambian female adults from ages 25 to 49 years.  
Ha4: There is a statistically significant association between demographic 
determinants and HIV serostatus of Zambian female adults from ages 25 to 49 years. 
Research question 5. What is the association between clinical determinants and 
HIV serostatus of Zambian female adolescents from ages 18 to 24 years? 
Ho5: There is no statistically significant association between clinical determinants 
and that of HIV serostatus of Zambian female adolescents from ages 18 to 24 years.  
Ha5: There is a statistically significant association between clinical determinants 
and HIV serostatus in Zambian female adolescents from ages 18 to 24 years.  
Research question 6. What is the association between clinical determinants and 
HIV serostatus of Zambian female adults from ages 25 to 49 years? 
Ho6: There is no statistically significant association between clinical determinants 
and that of HIV serostatus of Zambian female adults from ages 25 to 49 years.  
Ha6: There is a statistically significant association between clinical determinants 
and HIV serostatus in Zambian female adults from ages 25 to 49 years.  
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Research Question 7: What is the synergistic association between behavioral, 
demographic, and clinical determinants and that of HIV serostatus of Zambian 
adolescents from ages 18 to 24? years  
Ho7: There is no statistically significant synergistic association between 
behavioral, demographic, and clinical determinants and that of HIV serostatus of 
Zambian female adolescents from ages 18 to 24 years.  
Ha7: There is a statistically significant synergistic association between behavioral, 
demographic, and clinical determinants and that of HIV serostatus in Zambian female 
adolescents from ages 18 to 24 years.  
Research Question 8: What is the synergistic association between behavioral, 
demographic, and clinical determinants and that of HIV serostatus of Zambian adults 
from ages 25 to 49 years? 
Ho8: There is no statistically significant synergistic association between 
behavioral, demographic, and clinical determinants and that of HIV serostatus of 
Zambian female adults from ages 25 to 49 years.  
Ha8: There is a statistically significant synergistic association between behavioral, 
demographic, and clinical determinants and that of HIV serostatus in Zambian female 
adults from ages 25 to 49 years. 
Data Analysis Plan 
For this study, a data-driven approach will be applied to answer the research 
questions by using the Zambia demographic health survey data available in the Walden 
University Inter-University Consortium for Political and Social Research (ICPSR) 
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databases (Cheng & Phillips, 2014). This study utilized quantitative variables. The 
outcome variables were HIV serostatus (HIV positive, HIV negative, unknown status, 
and serodiscordant status). The independent variables were a sexual activity, number of 
sexual partners, condom use, fertility preferences (behavioral determinants), age, gender, 
location, marital status, education, employment (demographic determinants), clinical 
services, and medication adherence (clinical determinants).  
The confounding variables in these survey data were handled using a 
proportionate stratified sampling. The proportionate stratified sampling dealt with the 
selection of the study participants based on the stratum of the sampling frame for 
appropriate sampling representation (Salazar, Crosby, & DiClemente, 2015; Bankole, 
2017). The Statistical Package for the Social Sciences (SPSS) version 25 was used for all 
the analyses and statistical significance tests with a p-value ≤ 0.05. 
Preparing the Data 
Cleaning data 
The most common source of errors was missing data, coding errors, errors in data 
entry, inconsistency in responses, extreme outliers, abnormal distributions, and non-linear 
association among quantitative variables (Warner, 2013; Borkotoky & Unisa, 2014). 
Descriptive statistics for quantitative variables help to detect those errors by providing 
frequency tables, scatterplots, histograms, and observing whether the distribution shapes 
are approximately normally distributed (Warner, 2013). SPSS (version 25) was used for 
analysis and managing missing data by list-wise or pairwise deletions (Warner, 2013). 
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Multivariate analysis of variance (MANOVA) statistical tests was used to test this study’s 
hypotheses.  
This study contained multiple independent variables and three dependent 
variables. A multivariate analysis of variance (MANOVA) was used to test these 
hypotheses. As enumerated by Warner (2013), the statistical analysis procedure steps for 
multivariate analysis of variance were followed to assess the association between the 
independent variables and dependent variables of this study. In addition, an extensive 
description of the statistical significance testing is provided in the result section of this 
dissertation, and the meanings of these test results are discussed in depth. 
 There was no rationale for the inclusion of potential covariates for this two-way 
MANOVA. Data analyzers were required to observe the normal distribution (to transform 
or remove outliers if they exist); linearity (deviation from linearity compromises the 
analysis); homogeneity of variances (test of Homoscedasticity); homogeneity of 
variances and covariances (testing the homogeneousness of the dependent variables); and 
proceeded to the analyses (Warner, 2013). 
Threats to Validity  
External Validity 
 The survey data were collected using an equal probability of systematic 
sampling. Therefore, the probability of systematic sampling provided equal opportunity 
for selection; then, the sample of the survey was the representative of the population. This 
survey description clearly stated all households in Zambia had an equal likelihood of 
being selected as a part of the Zambia Demographic health survey sample with the 
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deliberate exclusion of restricted areas, such as military camps (Bankole, 2017). 
Therefore, the sample of community survey (Zambia demographic health survey) was 
representative of the population since each household had the probability of being 
selected from the whole population (Creswell, 2014). 
Internal Validity 
This Zambia demographic health survey applied proportional stratified sampling 
which was an accurate description of the broader population. The standardized 
questionnaire used further confirmed the internal validity of survey data (Babbie, 2017). 
After the survey data collection, the researchers removed temporary variables and labeled 
those variables with “temp” in the variable label. Some original variables in the dataset 
contained invalid values and discrepancies in the original variables. Those invalid 
variables and variables with differences were recorded. The data collector research 
institute advised me to use the recoded variables (cleaned data) for analysis and 
comparing cross-checking the recoded variables with the original ones would be 
necessary to perform data cleaning before performing analyses for this study (Bankole, 
2017). 
Ethical Procedures 
Ethical procedures were the formal requirements for conducting this study. I 
gained access to the archived data through the Institutional Research Board at Walden 
University. Institutional permissions, IRB approval, and the IRB approval numbers will 
be described in the final dissertation. The data description indicated the data were 
anonymous and personal information identifications were excluded to protect the 
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anonymity of study participants. The dataset is publicly available and could be accessed 
through a formal request to the Guttmacher Center for Population Research Innovation 
and Dissemination who prepared this public-use dataset. The research institute provided 
no incentives for participation in the survey.  
Summary 
A demographic survey data collected in Zambia from 2009–2010 assessed the 
association between behavioral, demographic, and clinical determinants of HIV 
serostatus in Zambian women. The collection of demographic health survey data was 
from 1,4441 Zambian women 18-49 years old; the survey included questions about issues 
of fertility preferences; HIV status; fertility preferences; attitudes toward and knowledge 
about HIV; and attitudes toward and use of HIV services. Demographic variables 
included age, location, native language, education, religion, and marital status. 
Independent variables included behavioral factors (condom use, sexual partners, fertility 
preferences, sexual activity, and attitudes toward and knowledge about HIV), 
demographic factors (age, location, native language, education, religion, and marital 
status), and clinical factors (use of services and attitudes toward, attitudes toward and use 
of HIV services). Dependent variables were HIV test result, ever tested for HIV, and ever 
tested AIDS. HIV positive (HIV concordant positive couple, HIV discordant male, and 
HIV discordant female): each indicates HIV seropositivity. HIV negative (HIV 
concordant negative couple, HIV discordant male, and HIV discordant female): each 
shows HIV seronegativity.  
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Chapter 4: Results 
Introduction 
The purpose of the study was to investigate the association between dependent 
variables measuring HIV serostatus (whether participants know their HIV test result, ever 
tested for HIV, and whether participants had ever tested for AIDS) behavioral 
determinants (participants’ sexual partners, condom use, and self-perceived HIV risk), 
demographic determinants (participants’ location, education, and marital status), and 
clinical determinants (participants’ use of government services, clinic services, and NGO 
services) for Zambian women aged 18–49 years using secondary data collected in 2009–
2010. I compared adolescents (aged 18–24 years) to adults (aged 25–49 years) to 
determine whether there were differences in the associations between behavioral, 
demographic, and clinical determinants and HIV serostatus between these age groups. 
The research questions that directed the study, along with the corresponding null 
and alternative hypotheses, were as follows. 
Research Question 1 
What is the association between behavioral determinants and HIV serostatus of 
Zambian women aged 18–24 years?  
H10: There is no statistically significant association between behavioral 
determinants and HIV serostatus of Zambian women aged 18–24 years. 
H1a: There is a statistically significant association between behavioral 
determinants and HIV serostatus of Zambian women aged 18–24 years.  
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Research Question 2 
What is the association between behavioral determinants and HIV serostatus of 
Zambian women aged 25–49 years?  
H20: There is no statistically significant association between behavioral 
determinants and HIV serostatus of Zambian women aged 25–49 years. 
H2a: There is a statistically significant association between behavioral 
determinants and HIV serostatus of Zambian women aged 25–49 years.  
Research Question 3 
What is the association between demographic determinants and HIV serostatus of 
Zambian women aged 18–24 years?  
H30: There is no statistically significant association between demographic 
determinants and HIV serostatus of Zambian women aged 18–24 years. 
H3a: There is a statistically significant association between demographic 
determinants and HIV serostatus of Zambian women aged 18–24 years.  
Research Question 4 
What is the association between demographic determinants and HIV serostatus of 
Zambian women aged 25–49 years?  
H40: There is no statistically significant association between demographic 
determinants and HIV serostatus of Zambian women aged 25–49 years.  
H4a: There is a statistically significant association between demographic 
determinants and HIV serostatus of Zambian women aged 25–49 years. 
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Research Question 5 
What is the association between clinical determinants and HIV serostatus of 
Zambian women aged 18–24 years? 
H50: There is no statistically significant association between clinical determinants 
and HIV serostatus of Zambian women aged 18–24 years.  
H5a: There is a statistically significant association between clinical determinants 
and HIV serostatus of Zambian women aged 18–24 years.  
Research Question 6 
What is the association between clinical determinants and HIV serostatus of 
Zambian women aged 25–49 years? 
H60: There is no statistically significant association between clinical determinants 
and HIV serostatus of Zambian women aged 25–49 years. 
H6a: There is a statistically significant association between clinical determinants 
and HIV serostatus of Zambian women aged 25–49 years.  
Research Question 7 
What is the synergistic association between behavioral, demographic, and clinical 
determinants and HIV serostatus of Zambian women aged 18–24 years?  
H70: There is no statistically significant synergistic association between 
behavioral, demographic, and clinical determinants and HIV serostatus of Zambian 
women aged 18–24 years.  
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H7a: There is a statistically significant synergistic association between behavioral, 
demographic, and clinical determinants and HIV serostatus of Zambian women aged 18–
24 years.  
Research Question 8 
What is the synergistic association between behavioral, demographic, and clinical 
determinants and that of HIV serostatus of Zambian women aged 25–49 years? 
H80: There is no statistically significant synergistic association between 
behavioral, demographic, and clinical determinants and HIV serostatus of Zambian 
women aged 25–49 years.  
H8a: There is a statistically significant synergistic association between behavioral, 
demographic, and clinical determinants and HIV serostatus of Zambian women aged 25–
49 years. 
Data Collection 
I obtained the secondary data from the ZDHS identified via the Walden 
University database. Data collected for the ZDHS came from participants in the Northern 
and Lusaka Provinces in 2009–2010. 
Results 
Demographics 
The sample from the ZDHS consisted of 1,441 women aged 18–49 years from 
Northern and Lusaka Provinces who were permanent residents of Zambia. Out of these 
participants, 442 (31%) were adolescents, and 999 (69%) were adults. Regarding 
location, 641 participants (44.5%) were from urban locations, and 800 (55.4%) were from 
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rural locations. Of those aged 18–24 years, 181 were urban, and 211 were rural; of those 
aged 25–49 years, 393 were urban, and 485 were rural. Tables 1–3 show cross-
tabulations of several of the variables. 
Table 1 
 
Cross-tabulation of Education × Location for Zambian Women Aged 18–49 Years 
Education 
Location 
Total Urban Rural 
Primary 227 432 659 
Secondary 267 185 452 
Higher 43 16 59 
N/A 40 74 114 
Total 577 707 1,284 
Note. N/A = not available response.  
Table 2 
Cross-tabulation of Marital Status × Location for Zambian Women Aged 18–49 Years 
old 
Marital status 
Location 
Total Urban Rural 
Widowed 45 32 77 
Divorced 25 23 48 
Separated 24 31 55 
N/A 481 618 1,099 
Total 575 704 1,279 
Note. N/A = not available response.  
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Table 3 
 
Descriptive Statistics for Dependent Variables and Clinical Determinants of Zambian 
Women Aged 18–49 Years 
Government Services × Clinic Services 
and NGO services M SD n 
HIV test result 
Yes × Yes    
Yes 18.76 34.517 41 
No 32.62 41.405 168 
Total 29.90 40.448 209 
Yes × No    
Yes 32.12 41.200 154 
No 36.68 42.209 816 
Total 35.96 42.063 970 
No × Yes    
Yes 2.00 0.000 3 
No 32.92 42.177 25 
Total 29.61 40.940 28 
No × No    
Yes 2.00 — 1 
No 44.93 44.698 14 
Total 42.07 44.475 15 
No × All    
Yes 2.00 0.000 4 
No 37.23 42.908 39 
Total 33.95 42.106 43 
N/A × N/A    
N/A 88.00 0.000 7 
Total 88.00 0.000 7 
Ever tested HIV 
Yes × Yes    
Yes 1.00 0.000 41 
No 1.00 0.000 168 
Total 1.00 0.000 209 
Yes × No    
Yes 1.00 0.000 154 
No 1.00 0.035 816 
Total 1.00 0.032 970 
No × Yes    
Yes 1.00 0.000 3 
No 1.00 0.000 25 
Total 1.00 0.000 28 
(table continues)  
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Government Services × Clinic Services 
and NGO services M SD n 
    
No × No    
Yes 1.00 — 1 
No 1.00 0.000 14 
Total 1.00 0.000 15 
N/A × N/A    
N/A 2.00 0.000 7 
Total 2.00 0.000 7 
N/A × All    
N/A 2.00 0.000 7 
Total 2.00 0.000 7 
Ever tested AIDS 
Yes × Yes    
Yes 1.00 0.000 41 
No 1.00 0.000 168 
Total 1.00 0.000 209 
Yes × No    
Yes 1.00 0.000 154 
No 1.00 0.000 816 
Total 1.00 0.000 970 
No × Yes    
Yes 1.00 0.000 3 
No 1.00 0.000 25 
Total 1.00 0.000 28 
No × No    
Yes 1.00 — 1 
No 1.00 0.000 14 
Total 1.00 0.000 15 
N/A × N/A    
N/A 2.00 0.000 7 
Total 2.00 0.000 7 
N/A × N/A    
N/A 2.00 0.000 7 
Total 2.00 0.000 7 
Note. NGO = nongovernmental organization.  
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The sample for this study consisted of 1251 Zambian adolescent women aged 18-
24 and 190 Zambian adult women aged 25 - 49. Figure 4 shows the frequencies for the 
HIV serostatus test for Zambian women aged 18–24 years (see figure 4).  
 
Figure 4. HIV status for Zambian women aged 18–24 years. Note. N/A = no reply   
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Figure 5 illustrates for the variable ever tested AIDS, revealing that eight women 
(0.55%) refused to be tested for AIDS, and 1433 (99.45) women were tested for AIDS of 
the Zambian women aged 18–49.  
 
Figure 5. Pie graph for the variable ever tested AIDS in Zambian women aged 18–49 
years. 
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Hypothesis Testing 1 
Hypothesis 1 was as follows: There is no statistically significant association 
between behavioral determinants and HIV serostatus of Zambian female adolescents 
from ages 18 - 24. Tables 4, 5, and 6 indicated the test results of this hypothesis.   
The MANOVA demonstrated a statistically significant (p< 0.01) for the 
association between the independent variable self-perceived HIV risk and the dependent 
variables HIV serostatus: HIV test result, ever tested HIV (see Table 4). Therefore, there 
is an association between the independent variables and the dependent variables for 
Zambian women aged 18–24 (see Table 4). Thus, I accepted the alternative hypothesis 
and rejected the null hypothesis.  
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Table 4 
 
Multivariate Tests on Behavioral Determinants of HIV Serostatus for Zambian Women Aged 18–24 Years 
   df   
Effect and testa Value F Hypothesis Error p Partial η2 
Intercept       
Pillai’s trace 0.990 57,877.883b 2 1204 .000 .990 
Wilks’s lambda 0.010 57,877.883b 2 1204 .000 .990 
Hotelling’s trace 96.143 57,877.883b 2 1204 .000 .990 
Roy’s largest root 96.143 57,877.883b 2 1204 .000 .990 
Sexual partners       
Pillai’s trace 0.001 0.623b 2 1204 .537 .001 
Wilks’s lambda 0.999 0.623b 2 1204 .537 .001 
Hotelling’s trace 0.001 0.623b 2 1204 .537 .001 
Roy’s largest root 0.001 0.623b 2 1204 .537 .001 
Condom use       
Pillai’s trace 0.004 2.265b 2 1204 .104 .004 
Wilks’s lambda 0.996 2.265b 2 1204 .104 .004 
Hotelling’s trace 0.004 2.265b 2 1204 .104 .004 
Roy’s largest root 0.004 2.265b 2 1204 .104 .004 
Self-perceived HIV risk        
Pillai’s trace 0.897 163.283 12 2410 .000 .448 
Wilks’s lambda 0.121 375.987b 12 2408 .000 .652 
Hotelling’s trace 7.110 712.751 12 2406 .000 .780 
Roy’s largest root 7.089 1,423.669c 6 1205 .000 .876 
Sexual Partners × Condom Use       
Pillai’s trace 0.001 0.619b 2 1204 .539 .001 
Wilks’s lambda 0.999 0.619b 2 1204 .539 .001 
Hotelling’s trace 0.001 0.619b 2 1204 .539 .001 
         (table continues) 
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   df   
Effect and testa Value F Hypothesis Error p Partial η2 
Roy’s largest root 0.001 0.619b 2 1204 .539 .001 
Sexual Partners × Self-Perceived HIV Risk        
Pillai’s trace 0.001 0.256 4 2410 .906 .000 
Wilks’s lambda 0.999 0.256b 4 2408 .906 .000 
Hotelling’s trace 0.001 0.256 4 2406 .906 .000 
Roy’s largest root 0.001 0.512c 2 1205 .599 .001 
Condom Use × Self-Perceived HIV Risk        
Pillai’s trace 0.002 0.500 4 2410 .736 .001 
Wilks’s lambda 0.998 0.500b 4 2408 .736 .001 
Hotelling’s trace 0.002 0.500 4 2406 .736 .001 
Roy’s largest root 0.002 0.921c 2 1205 .398 .002 
Sexual Partners × Condom Use × Self-Perceived HIV Risk        
Pillai’s trace 0.000 0.175b 2 1204 .840 .000 
Wilks’s lambda 1.000 0.175b 2 1204 .840 .000 
Hotelling’s trace 0.000 0.175b 2 1204 .840 .000 
Roy’s largest root 0.000 0.175b 2 1204 .840 .000 
aDesign: Intercept + SEXPARTN + CONDOUSE + HIVSELFRISK + SEXPARTN * CONDOUSE + SEXPARTN * 
HIVSELFRISK + CONDOUSE * HIVSELFRISK + SEXPARTN * CONDOUSE * HIVSELFRISK. bExact statistic. cThe 
statistic is an upper bound on F that yields a lower bound on the significance level. 
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Table 5 presented the result of MANOVA using Tukey’s Honestly Significant 
Difference for Behavioral Determinants of HIV Serostatus for Zambian Women Aged 
18–24 Years. The results of the MANOVA indicated the following results for Zambian 
women aged 18–24 years: 
1. Mean scores for HIV test result were statistically significantly different 
between the no risk at all and small risk conditions (p < .001), the no risk at 
all and has AIDS conditions (p < .001), the small and has AIDS conditions (p 
= .012), the small and don’t know conditions (p =.039), the moderate and has 
AIDS conditions (p = .027), and the great and has AIDS conditions (p < .001). 
2. Mean scores for the ever tested HIV were statistically significantly different 
between the moderate and has AIDS conditions (p = .027). 
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Table 5 
 
Tukey’s Honestly Significant Difference for Behavioral Determinants of HIV Serostatus 
for Zambian Women Aged 18–24 Years 
HIV self−perceived risks (I & J) Mean difference (I − J) SE p 
95% CI 
LL UL 
Dependent variable: HIV test result 
No risk at all      
Small 14.66 2.633 .000 6.88 22.43 
Moderate 11.80 5.700 .371 −5.03 28.64 
Great 2.97 5.569 .998 −13.48 19.41 
Has AIDS 41.38 7.806 .000 18.33 64.43 
Don’t know −0.10 4.774 1.000 −14.20 14.00 
Small      
No risk at all −14.66 2.633 .000 −22.43 −6.88 
Moderate −2.86 5.775 .999 −19.91 14.20 
Great −11.69 5.646 .371 −28.37 4.98 
Has AIDS 26.72 7.860 .012 3.51 49.94 
Don’t know −14.76 4.863 .039 −29.12 −0.40 
Moderate      
No risk at all −11.80 5.700 .371 −28.64 5.03 
Small 2.86 5.775 .999 −14.20 19.91 
Great −8.84 7.579 .907 −31.22 13.55 
Has AIDS 29.58 9.346 .027 1.98 57.18 
Don’t know −11.90 7.015 .618 −32.62 8.81 
Great      
No risk at all −2.97 5.569 .998 −19.41 13.48 
Small 11.69 5.646 .371 −4.98 28.37 
Moderate 8.84 7.579 .907 −13.55 31.22 
Has AIDS 38.42 9.267 .001 11.05 65.78 
Don’t know −3.07 6.909 .999 −23.47 17.34 
Has AIDS      
No risk at all −41.38 7.806 .000 −64.43 −18.33 
Small −26.72 7.860 .012 −49.94 −3.51 
Moderate −29.58 9.346 .027 −57.18 −1.98 
Great −38.42 9.267 .001 −65.78 −11.05 
Don’t know −41.48 8.811 .000 −67.51 −15.46 
Don’t know      
No risk at all 0.10 4.774 1.000 −14.00 14.20 
Small 14.76 4.863 .039 0.40 29.12 
Moderate 11.90 7.015 .618 −8.81 32.62 
Great 3.07 6.909 .999 −17.34 23.47 
Has AIDS 41.48 8.811 .000 15.46 67.51 
Dependent variable: ever tested HIV 
No risk at all      
Small 0.00 0.002 .957 0.00 0.01 
Moderate 0.00 0.004 .999 −0.01 0.01 
Great 0.00 0.004 .999 −0.01 0.01 
Has AIDS 0.00 0.005 1.000 −0.01 0.02 
Don’t know 0.00 0.003 .998 −0.01 0.01 
No risk at all 0.00 0.002 .957 −0.01 0.00 
     (table continues)     
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HIV self−perceived risks (I & J) Mean difference (I − J) SE p 
95% CI 
LL UL 
Moderate 0.00 0.004 1.000 −0.01 0.01 
Great 0.00 0.004 1.000 −0.01 0.01 
Has AIDS 0.00 0.005 1.000 −0.02 0.02 
Don’t know 0.00 0.003 1.000 −0.01 0.01 
Moderate      
No risk at all 0.00 0.004 .999 −0.01 0.01 
Small 0.00 0.004 1.000 −0.01 0.01 
Great 0.00 0.005 1.000 −0.02 0.02 
Has AIDS 0.00 0.007 1.000 −0.02 0.02 
Don’t know 0.00 0.005 1.000 −0.01 0.01 
Great      
No risk at all 0.00 0.004 .999 −0.01 0.01 
Small 0.00 0.004 1.000 −0.01 0.01 
Moderate 0.00 0.005 1.000 −0.02 0.02 
Has AIDS 0.00 0.006 1.000 −0.02 0.02 
Don’t know 0.00 0.005 1.000 −0.01 0.01 
Has AIDS      
No risk at all 0.00 0.005 1.000 −0.02 0.01 
Small 0.00 0.005 1.000 −0.02 0.02 
Moderate 0.00 0.007 1.000 −0.02 0.02 
Great 0.00 0.006 1.000 −0.02 0.02 
Don’t know 0.00 0.006 1.000 −0.02 0.02 
Don’t know      
No risk at all 0.00 0.003 .998 −0.01 0.01 
Small 0.00 0.003 1.000 −0.01 0.01 
Moderate 0.00 0.005 1.000 −0.01 0.01 
Great 0.00 0.005 1.000 −0.01 0.01 
Has AIDS 0.00 0.006 1.000 −0.02 0.02 
Note. CI = confidence interval; LL = lower limit; UL = upper limit. 
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Table 6 demonstrates a statistically significant association between condom use 
and HIV test result, F(1, 1222) = 0.334, p = .042, Partial η2 = .003 for Tests of Between-
Subjects Effects on Behavioral Determinants of HIV Serostatus for Zambian Women 
Aged 18–24 years. The association between self-perceived HIV risk and HIV test result, 
F(1, 1222) = 6.195, p < .001, Partial η2 = 0.030 and the association between self-
perceived HIV risk and ever tested HIV, F(1, 122) = 1418.284, p < .001, Partial η2 = 
0.876 were statistically significant for women aged 18–24 (see table 6). Finally, Tables 4, 
5, and 6 confirmed for the acceptance of the alternative hypothesis for the hypothesis 
testing 1.
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Table 6 
 
Tests of Between-Subjects Effects on Behavioral Determinants of HIV Serostatus for Zambian Women Aged 18–24 Years 
Source and dependent variable 
Type III sum of 
squares df Mean square F p Partial η2 
Corrected model       
HIV test result 135,714.155a 16 8,482.135 5.052 .000 .063 
Ever tested HIV 6.963b 16 0.435 532.897 .000 .876 
Ever tested AIDS 6.960c 16 0.435 — — 1.000 
Intercept       
HIV test result 74,934.645 1 74,934.645 44.635 .000 .036 
Ever tested HIV 94.435 1 94.435 115,629.835 .000 .990 
Ever tested AIDS 94.287 1 94.287 — — 1.000 
Sexual partners       
HIV test result 2,090.963 1 2,090.963 1.245 .265 .001 
Ever tested HIV 0.000 1 0.000 0.000 1.000 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
Condom use       
HIV test result 6,950.334 1 6,950.334 4.140 .042 .003 
Ever tested HIV 0.000 1 0.000 0.334 .563 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
Self-perceived HIV risk       
HIV test result 62,399.854 6 10,399.976 6.195 .000 .030 
Ever tested HIV 6.950 6 1.158 1,418.284 .000 .876 
Ever tested AIDS 6.949 6 1.158 — — 1.000 
Sexual Partners × Condom Use       
HIV test result 2,077.320 1 2,077.320 1.237 .266 .001 
Ever tested HIV 0.000 1 0.000 0.000 1.000 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
(table continues)  
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Source and dependent variable 
Type III sum of 
squares df Mean square F p Partial η2 
Sexual Partners × Self-Perceived HIV Risk       
HIV test result 1,717.791 2 858.896 0.512 .600 .001 
Ever tested HIV 0.000 2 0.000 0.000 1.000 .000 
Ever tested AIDS 0.000 2 0.000 — — — 
Condom Use × Self-Perceived HIV Risk       
HIV test result 2,411.591 2 1,205.796 0.718 .488 .001 
Ever tested HIV 0.000 2 0.000 0.266 .767 .000 
Ever tested AIDS 0.000 2 0.000 — — — 
Sexual Partners × Condom Use × Self-Perceived HIV Risk       
HIV test result 586.483 1 586.483 0.349 .555 .000 
Ever tested HIV 0.000 1 0.000 0.000 1.000 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
Error       
HIV test result 2,022,991.112 1205 1,678.831    
Ever tested HIV 0.984 1205 0.001    
Ever tested AIDS 0.000 1205 0.000    
Total       
HIV test result 3,728,050.000 1222     
Ever tested HIV 1246.000 1222     
Ever tested AIDS 1243.000 1222     
Corrected total       
HIV test result 2,158,705.267 1221     
Ever tested HIV 7.948 1221     
Ever tested AIDS 6.960 1221     
a. R Squared = .119 (Adjusted R Squared = .082) 
b. R Squared = 1.000 (Adjusted R Squared = 1.000) 
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Hypothesis Testing 2 
Hypothesis 2 described in the following way: there is no association between 
behavioral determinants and HIV serostatus of Zambian female adults from age 25 to 49.  
Tables 7, 8, and 9 demonstrated the MANOVA results to test hypothesis testing 2 for 
Zambian women aged 25 – 49. 
The multivariate analysis of variance (MANOVA) provided the following results 
for the association between  Self perceived HIV risk (no risk at all, small, moderate, 
great, has AIDS, don’t know) with   HIV serostatus (see table 7).  
1. The mean scores for HIV test result were statistically significantly different 
between the no risk at all and small conditions (p < .001), the no risk at all 
and has AIDS conditions (p < .001), the small and has AIDS conditions (p = 
.012), the small and don’t know conditions (p = .039), the moderate and has 
AIDS conditions (p = .027), and the great and has AIDS conditions (p < .001). 
2. The mean scores for the ever tested HIV were statistically significantly 
different between the moderate and has AIDS conditions (p = .027).  
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Table 7 
 
Tukey’s Honestly Significant Difference for Behavioral Determinants of HIV Serostatus 
for Zambian Women Aged 25-49 Years 
HIV self−perceived risks (I & J) Mean difference (I − J) SE p 
95% CI 
LL UL 
Dependent variable: HIV test result 
No risk at all      
Small 14.66 2.633 0.000 6.88 22.43 
Moderate 11.80 5.700 0.371 −5.03 28.64 
Great 2.97 5.569 0.998 −13.48 19.41 
Has AIDS 41.38 7.806 0.000 18.33 64.43 
Don’t know −0.10 4.774 1.000 −14.20 14.00 
Small      
No risk at all −14.66 2.633 0.000 −22.43 −6.88 
Moderate −2.86 5.775 0.999 −19.91 14.20 
Great −11.69 5.646 0.371 −28.37 4.98 
Has AIDS 26.72 7.860 0.012 3.51 49.94 
Don’t know −14.76 4.863 0.039 −29.12 −0.40 
Great      
No risk at all −2.97 5.569 0.998 −19.41 13.48 
Small 11.69 5.646 0.371 −4.98 28.37 
Moderate 8.84 7.579 0.907 −13.55 31.22 
Has AIDS 38.42 9.267 0.001 11.05 65.78 
Don’t know −3.07 6.909 0.999 −23.47 17.34 
Has AIDS      
No risk at all −41.38 7.806 0.000 −64.43 −18.33 
Small −26.72 7.860 0.012 −49.94 −3.51 
Moderate −29.58 9.346 0.027 −57.18 −1.98 
Great −38.42 9.267 0.001 −65.78 −11.05 
Don’t know −41.48 8.811 0.000 −67.51 −15.46 
Dependent variable: Ever tested HIV 
No risk at all      
Small 0.00 0.002 0.957 0.00 0.01 
Moderate 0.00 0.004 0.999 −0.01 0.01 
Great 0.00 0.004 0.999 −0.01 0.01 
Has AIDS 0.00 0.005 1.000 −0.01 0.02 
Don’t know 0.00 0.003 0.998 −0.01 0.01 
Great      
No risk at all 0.00 0.004 0.999 −0.01 0.01 
Small 0.00 0.004 1.000 −0.01 0.01 
Moderate 0.00 0.005 1.000 −0.02 0.02 
Has AIDS 0.00 0.006 1.000 −0.02 0.02 
Don’t know 0.00 0.005 1.000 −0.01 0.01 
N/A −1.00 0.011 0.000 −1.03 −0.97 
Note. CI = confidence interval; LL = lower limit; UL = upper limit. 
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 The multivariate tests in Table 8 were for associations between the dependent 
variables: HIV test result, ever tested HIV, and ever tested AIDS) and behavioral 
determinants: sexual partners, condom use, and self-perceived risk for women aged 25–
49. There was a statistically significant difference association between self-perceived 
HIV risk and a linear combination of the three dependent variables. In this main effect, 
self-perceived HIV risk was statistically significant: Pillai’s trace was 0.897, F(2, 2410) = 
163.283, p < .001; Wilks’s lambda = 0.121, partial η2 = .448. The other two variables, 
sexual partners and condom use were not statistically significant, and neither were 
associations between other combinations of the behavioral determinants (see table 8). 
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Table 8 
 
Multivariate Tests on Behavioral Determinants of HIV Serostatus on Zambian Women Aged 25–49 Years 
   df   
Effect and test Value F Hypothesis Error p Partial η2 
Intercept       
Pillai’s trace 0.990 57,877.883a 2 1204 .000 .990 
Wilks’s lambda 0.010 57,877.883a 2 1204 .000 .990 
Hotelling’s trace 96.143 57,877.883a 2 1204 .000 .990 
Roy’s largest root 96.143 57,877.883a 2 1204 .000 .990 
Sexual partners       
Pillai’s trace 0.001 0.623a 2 1204 .537 .001 
Wilks’s lambda 0.999 0.623a 2 1204 .537 .001 
Hotelling’s trace 0.001 0.623a 2 1204 .537 .001 
Roy’s largest root 0.001 0.623a 2 1204 .537 .001 
Condom use       
Pillai’s trace 0.004 2.265a 2 1204 .104 .004 
Wilks’s lambda 0.996 2.265a 2 1204 .104 .004 
Hotelling’s trace 0.004 2.265a 2 1204 .104 .004 
Roy’s largest root 0.004 2.265a 2 1204 .104 .004 
Self-perceived HIV risk        
Pillai’s trace 0.897 163.283 12 2410 .000 .448 
Wilks’s lambda 0.121 375.987a 12 2408 .000 .652 
Hotelling’s trace 7.110 712.751 12 2406 .000 .780 
Roy’s largest root 7.089 1,423.669b 6 1205 .000 .876 
Sexual Partners × Condom Use       
Pillai’s trace 0.001 0.619a 2 1204 .539 .001 
Wilks’s lambda 0.999 0.619a 2 1204 .539 .001 
Hotelling’s trace 0.001 0.619a 2 1204 .539 .001 
    (table continues)  
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   df   
Effect and test Value F Hypothesis Error p Partial η2 
 Roy’s largest root 0.001 0.619a 2 1204 .539 .001 
Sexual Partners × Self-Perceived HIV Risk        
Pillai’s trace 0.001 0.256 4 2410 .906 .000 
Wilks’s lambda 0.999 0.256a 4 2408 .906 .000 
Hotelling’s trace 0.001 0.256 4 2406 .906 .000 
Roy’s largest root 0.001 0.512b 2 1205 .599 .001 
Condom Use × Self-Perceived HIV Risk        
Pillai’s trace 0.002 0.500 4 2410 .736 .001 
Wilks’s lambda 0.998 0.500a 4 2408 .736 .001 
Hotelling’s trace 0.002 0.500 4 2406 .736 .001 
Roy’s largest root 0.002 0.921b 2 1205 .398 .002 
Sexual Partners × Condom Use × Self-Perceived HIV Risk        
Pillai’s trace 0.000 0.175a 2 1204 .840 .000 
Wilks’s lambda 1.000 0.175a 2 1204 .840 .000 
Hotelling’s trace 0.000 0.175a 2 1204 .840 .000 
Roy’s largest root 0.000 0.175a 2 1204 .840 .000 
a. Design: Intercept + SEXPARTN + CONDOUSE + HIVSELFRISK + SEXPARTN * CONDOUSE + SEXPARTN * 
HIVSELFRISK + CONDOUSE * HIVSELFRISK + SEXPARTN * CONDOUSE * HIVSELFRISK 
b. Exact statistic 
c. The statistic is an upper bound on F that yields a lower bound on the significance level 
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Table 9 were Tests of Between-Subjects Effects on Behavioral Determinants of 
HIV Serostatus for Zambian Women Aged 25–49 years on the associations between the 
dependent variables and behavioral determinants for women aged 25–49. there was a 
statistically significant association between condom use and HIV test result, F(1, 1222) = 
4.140, p = .04, self-perceived  HIV risk and HIV test result, F(1, 1222) = 6.195, p < .001, 
partial η2 = .030, and self-perceived HIV risk and ever tested HIV, F(1, 1222) = XX, p < 
.001, partial η2 = .776. Besides, there was a statistically significant difference association 
between self-perceived HIV risk and a linear combination of the three dependent 
variables. In this main effect, self-perceived HIV risk was statistically significant: F(2, 
1222) = 532.897, p < .001; partial η2 = .876. The other two variables, sexual partners and 
condom use, were not statistically significant with HIV test results (see table 9). 
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Table 9 
Tests of Between-Subjects Effects on Behavioral Determinants of HIV Serostatus for Zambian Women Aged 25–49 Years 
Source and dependent variable 
Type III sum of 
squares df Mean square F p 
Partial 
η2 
Corrected model       
HIV test result 135,714.155a 16 8482.135 5.052 .000 .063 
Ever tested HIV 6.963b 16 0.435 532.897 .000 .876 
Ever tested AIDS 6.960c 16 0.435 — — 1.000 
Intercept       
HIV test result 74,934.645 1 74,934.645 44.635 .000 .036 
Ever tested HIV 94.435 1 94.435 115,629.835 .000 .990 
Ever tested AIDS 94.287 1 94.287 — — 1.000 
Sexual partners       
HIV test result 2,090.963 1 2,090.963 1.245 .265 .001 
Ever tested HIV 0.000 1 0.000 0.000 1.000 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
Condom use       
HIV test result 6,950.334 1 6,950.334 4.140 .042 .003 
Ever tested HIV 0.000 1 0.000 0.334 .563 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
Self-perceived HIV risk       
HIV test result 62,399.854 6 10,399.976 6.195 .000 .030 
Ever tested HIV 6.950 6 1.158 1,418.284 .000 .876 
Ever tested AIDS 6.949 6 1.158 — — 1.000 
Sexual Partners × Condom Use       
HIV test result 2,077.320 1 2,077.320 1.237 .266 .001 
Ever tested HIV 0.000 1 0.000 0.000 1.000 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
 (table continues)  
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Source and dependent variable 
Type III sum of 
squares df Mean square F p 
Partial 
η2 
Sexual Partners × Self-Perceived HIV Risk       
HIV test result 1,717.791 2 858.896 0.512 .600 .001 
Ever tested HIV 0.000 2 0.000 0.000 1.000 .000 
Ever tested AIDS 0.000 2 0.000 — — — 
Condom Use × Self-Perceived HIV Risk       
HIV test result 2,411.591 2 1,205.796 0.718 .488 .001 
Ever tested HIV 0.000 2 0.000 0.266 .767 .000 
Ever tested AIDS 0.000 2 0.000 — — — 
Sexual Partners × Condom Use × Self-Perceived HIV Risk       
HIV test result 586.483 1 586.483 0.349 .555 .000 
Ever tested HIV 0.000 1 0.000 0.000 1.000 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
Error       
HIV test result 2,022,991.112 1205 1,678.831    
Ever tested HIV 0.984 1205 0.001    
Ever tested AIDS 0.000 1205 0.000    
Total       
HIV test result 3,728,050.000 1222     
Ever tested HIV 1246.000 1222     
Ever tested AIDS 1243.000 1222     
Corrected total       
HIV test result 2,158,705.267 1221     
Ever tested HIV 7.948 1221     
Ever tested AIDS 6.960 1221     
a. R Squared = .053 (Adjusted R Squared = .036) 
b. R Squared = .804 (Adjusted R Squared = .800) 
c. R Squared = 1.000 (Adjusted R Squared = 1.000) 
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Hypothesis Testing 3 
Hypothesis 3 developed as follows: there is no statistically significant association 
between demographic determinants and HIV serostatus of Zambian female adolescents 
from ages 18 to 24. Tables 10 and 11 indicate the  MANOVA results of hypothesis 
testing 3 by analyzing the associations between demographic determinants (location, 
education, and marital status) with the dependent variable HIV serostatus. It appeared a 
statistically significant association between education and a linear combination of the 
three dependent variables (see table 10).   
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Table 10 
 
Multivariate Tests on Demographic Determinants of HIV Serostatus on Zambian Women Aged 18–24 Years 
   df   
Effect and testa Value F Hypothesis Error p Partial η2 
Intercept       
Pillai’s trace 0.927 5,109.357b 3 1215.000 .000 .927 
Wilks’s lambda 0.073 5,109.357b 3 1215.000 .000 .927 
Hotelling’s trace 12.616 5,109.357b 3 1215.000 .000 .927 
Roy’s largest root 12.616 5,109.357b 3 1215.000 .000 .927 
Location       
Pillai’s trace 0.002 0.914b 3 1215.000 .433 .002 
Wilks’s lambda 0.998 0.914b 3 1215.000 .433 .002 
Hotelling’s trace 0.002 0.914b 3 1215.000 .433 .002 
Roy’s largest root 0.002 0.914b 3 1215.000 .433 .002 
Education       
Pillai’s trace 0.015 2.099 9 3651.000 .026 .005 
Wilks’s lambda 0.985 2.106 9 2957.141 .026 .005 
Hotelling’s trace 0.016 2.111 9 3641.000 .025 .005 
Roy’s largest root 0.015 5.930c 3 1217.000 .001 .014 
Marital status       
Pillai’s trace 0.003 0.363 9 3651.000 .953 .001 
Wilks’s lambda 0.997 0.363 9 2957.141 .953 .001 
Hotelling’s trace 0.003 0.362 9 3641.000 .953 .001 
Roy’s largest root 0.002 0.964c 3 1217.000 .409 .002 
Location × Education       
Pillai’s trace 0.002 0.225 9 3651.000 .991 .001 
Wilks’s lambda 0.998 0.224 9 2957.141 .991 .001 
Hotelling’s trace 0.002 0.224 9 3641.000 .991 .001 
    (table continues)     
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   df   
Effect and testa Value F Hypothesis Error p Partial η2 
 
Roy’s largest root 
0.001 0.496c 3 1217.000 .685 .001 
Location × Marital Status       
Pillai’s trace 0.004 0.588 9 3651.000 .808 .001 
Wilks’s lambda 0.996 0.588 9 2957.141 .808 .001 
Hotelling’s trace 0.004 0.588 9 3641.000 .808 .001 
Roy’s largest root 0.004 1.576c 3 1217.000 .193 .004 
Education × Marital Status       
Pillai’s trace 0.012 0.587 24 3651.000 .944 .004 
Wilks’s lambda 0.988 0.587 24 3524.471 .944 .004 
Hotelling’s trace 0.012 0.588 24 3641.000 .944 .004 
Roy’s largest root 0.010 1.449c 8 1217.000 .172 .009 
Location × Education × Marital Status       
Pillai’s trace 0.007 0.506 18 3651.000 .957 .002 
Wilks’s lambda 0.993 0.506 18 3437.024 .957 .002 
Hotelling’s trace 0.007 0.505 18 3641.000 .957 .002 
Roy’s largest root 0.005 1.039c 6 1217.000 .398 .005 
a. Design: Intercept + LOCATION + EDUCATION + MARITALST + LOCATION * EDUCATION + LOCATION * 
MARITALST + EDUCATION * MARITALST + LOCATION * EDUCATION * MARITALST 
b. Exact statistic 
c. The statistic is an upper bound on F that yields a lower bound on the significance level. 
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Table 11, Tests of Between-Subjects Effects on Zambian women aged 18 - 24,  showed a 
statistically significant association between education (demographic variable) and HIV 
serostatus,  F(3, 1245) = 5.992, p = .001, η2 =  0.14.  The association between 
demographic variables location and marital status had no statistically significant variation 
with the ever tested HIV and ever tested AIDS (see table 11). 
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Table 11 
 
Tests of Between-Subjects Effects on Demographic Determinants of HIV Serostatus on Zambian Women Aged 18–24 Years 
Source and dependent variable Type III sum of squares df Mean square F p Partial η2 
Corrected model       
HIV test result 107,571.421a 27 3,984.127 2.323 .000 .049 
Ever tested HIV 0.104b 27 0.004 0.596 .950 .013 
Ever tested AIDS 0.089c 27 0.003 0.582 .957 .013 
Intercept       
HIV test result 112,188.806 1 112,188.806 65.423 .000 .051 
Ever tested HIV 86.655 1 86.655 13,443.028 .000 .917 
Ever tested AIDS 86.629 1 86.629 15,341.789 .000 .927 
Location       
HIV test result 4,509.737 1 4,509.737 2.630 .105 .002 
Ever tested HIV 0.001 1 0.001 0.198 .657 .000 
Ever tested AIDS 0.001 1 0.001 0.241 .624 .000 
Education       
HIV test result 30,465.256 3 10,155.085 5.922 .001 .014 
Ever tested HIV 0.009 3 0.003 0.455 .714 .001 
Ever tested AIDS 0.008 3 0.003 0.460 .710 .001 
Marital status       
HIV test result 4,825.666 3 1,608.555 0.938 .422 .002 
Ever tested HIV 0.003 3 0.001 0.155 .926 .000 
Ever tested AIDS 0.003 3 0.001 0.176 .912 .000 
Location × Education       
HIV test result 1,840.615 3 613.538 0.358 .784 .001 
Ever tested HIV 0.005 3 0.002 0.253 .859 .001 
Ever tested AIDS 0.006 3 0.002 0.334 .801 .001 
Location × Marital Status       
  (table continues) 
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Source and dependent variable Type III sum of squares df Mean square F p Partial η2 
HIV test result 5,065.565 3 1,688.522 0.985 .399 .002 
Ever tested HIV 0.016 3 0.005 0.831 .477 .002 
Ever tested AIDS 0.015 3 0.005 0.895 .443 .002 
Education × Marital Status       
HIV test result 19,802.422 8 2,475.303 1.443 .174 .009 
Ever tested HIV 0.012 8 0.002 0.240 .983 .002 
Ever tested AIDS 0.013 8 0.002 0.284 .971 .002 
Location × Education × Marital Status       
HIV test result 10,603.796 6 1,767.299 1.031 .404 .005 
Ever tested HIV 0.018 6 0.003 0.459 .839 .002 
Ever tested AIDS 0.016 6 0.003 0.460 .838 .002 
Error       
HIV test result 2,086,936.408 1217 1,714.820    
Ever tested HIV 7.845 1217 0.006    
Ever tested AIDS 6.872 1217 0.006    
Total       
HIV test result 3,774,579.000 1245     
Ever tested HIV 1,269.000 1245     
Ever tested AIDS 1,266.000 1245     
Corrected total       
HIV test result 2,194,507.828 1244     
Ever tested HIV 7.949 1244     
Ever tested AIDS 6.961 1244     
a. R Squared = .067 (Adjusted R Squared = .026) 
b. R Squared = .111 (Adjusted R Squared = .071) 
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Hypothesis Testing 4 
Hypothesis 4 stated as follows: there is no statistically significant association 
between demographic determinants and HIV serostatus of Zambian female adolescents 
from age 25 – 49. Tests of Between-Subjects Effects report the result on associations 
between demographic determinants and HIV serostatus for Zambian women aged 25–49 
(see tables 12 and 13).  
One of the three demographic determinant variables, education, had a statistically 
association with HIV test result, F(3, 1217) = 5.922, p < .001, partial η2 = .014 (see table 
12).  In table 12, the other two demographic determinant variables, location, and marital 
status had no statistically significant association with ever tested HIV, ever tested AIDS  
(see table  12).
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Table 12 
 
Tests of Between-Subjects Effects on Demographic Determinants of HIV Serostatus on Zambian Women Aged 25–49 Years 
Source and dependent variable Type III sum of squares df Mean square F p Partial η2 
Corrected model       
HIV test result 107,571.421a 27 3,984.127 2.323 .000 .049 
Ever tested HIV 0.104b 27 0.004 0.596 .950 .013 
Ever tested AIDS 0.089c 27 0.003 0.582 .957 .013 
Intercept       
HIV test result 112,188.806 1 112,188.806 65.423 .000 .051 
Ever tested HIV 86.655 1 86.655 13,443.028 .000 .917 
Ever tested AIDS 86.629 1 86.629 15,341.789 .000 .927 
Location       
HIV test result 4,509.737 1 4,509.737 2.630 .105 .002 
Ever tested HIV 0.001 1 0.001 0.198 .657 .000 
Ever tested AIDS 0.001 1 0.001 0.241 .624 .000 
Education       
HIV test result 30,465.256 3 10,155.085 5.922 .001 .014 
Ever tested HIV 0.009 3 0.003 0.455 .714 .001 
Ever tested AIDS 0.008 3 0.003 0.460 .710 .001 
Marital status       
HIV test result 4,825.666 3 1,608.555 0.938 .422 .002 
Ever tested HIV 0.003 3 0.001 0.155 .926 .000 
Ever tested AIDS 0.003 3 0.001 0.176 .912 .000 
Location × Education       
HIV test result 1,840.615 3 613.538 0.358 .784 .001 
Ever tested HIV 0.005 3 0.002 0.253 .859 .001 
Ever tested AIDS 0.006 3 0.002 0.334 .801 .001 
Location × Marital Status       
 (table continues) 
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Source and dependent variable Type III sum of squares df Mean square F p Partial η2 
HIV test result 5,065.565 3 1,688.522 0.985 .399 .002 
Ever tested HIV 0.016 3 0.005 0.831 .477 .002 
Ever tested AIDS 0.015 3 0.005 0.895 .443 .002 
Education × Marital Status       
HIV test result 19,802.422 8 2,475.303 1.443 .174 .009 
Ever tested HIV 0.012 8 0.002 0.240 .983 .002 
Ever tested AIDS 0.013 8 0.002 0.284 .971 .002 
Location × Education × Marital Status       
HIV test result 10,603.796 6 1,767.299 1.031 .404 .005 
Ever tested HIV 0.018 6 0.003 0.459 .839 .002 
Ever tested AIDS 0.016 6 0.003 0.460 .838 .002 
Error       
HIV test result 2,086,936.408 1217 1,714.820    
Ever tested HIV 7.845 1217 0.006    
Ever tested AIDS 6.872 1217 0.006    
Total       
HIV test result 3,774,579.000 1245     
Ever tested HIV 1,269.000 1245     
Ever tested AIDS 1,266.000 1245     
Corrected total       
HIV test result 2,194,507.828 1244     
Ever tested HIV 7.949 1244     
Ever tested AIDS 6.961 1244     
a. R Squared = .071 (Adjusted R Squared = .041) 
b. R Squared = .010 (Adjusted R Squared = -.022) 
c. R Squared = .006 (Adjusted R Squared = -.026) 
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Table 13 indicates a statistically significant association between education and the 
linear combination of the dependent variable for women aged 25–49 years. In this main 
effect education was statistically significant in its association with HIV serostatus: 
Pillai’s trace was 0.015, F(9, 3651) = 2.099, p = .026; Wilks’s lambda was 0.985, partial 
η2 = .005.  
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Table 13 
 
Multivariate Tests on Demographic Determinants of HIV Serostatus on Zambian Women Aged 25–49 Years 
   df   
Effect and testa Value F Hypothesis Error p Partial η2 
Intercept       
Pillai’s trace 0.927 5,109.357b 3 1215.000 .000 .927 
Wilks’s lambda 0.073 5,109.357b 3 1215.000 .000 .927 
Hotelling’s trace 12.616 5,109.357b 3 1215.000 .000 .927 
Roy’s largest root 12.616 5,109.357b 3 1215.000 .000 .927 
Location       
Pillai’s trace 0.002 0.914b 3 1215.000 .433 .002 
Wilks’s lambda 0.998 0.914b 3 1215.000 .433 .002 
Hotelling’s trace 0.002 0.914b 3 1215.000 .433 .002 
Roy’s largest root 0.002 0.914b 3 1215.000 .433 .002 
Education       
Pillai’s trace 0.015 2.099 9 3651.000 .026 .005 
Wilks’s lambda 0.985 2.106 9 2957.141 .026 .005 
Hotelling’s trace 0.016 2.111 9 3641.000 .025 .005 
Roy’s largest root 0.015 5.930c 3 1217.000 .001 .014 
Marital status       
Pillai’s trace 0.003 0.363 9 3651.000 .953 .001 
Wilks’s lambda 0.997 0.363 9 2957.141 .953 .001 
Hotelling’s trace 0.003 0.362 9 3641.000 .953 .001 
Roy’s largest root 0.002 0.964c 3 1217.000 .409 .002 
Location × Education       
Pillai’s trace 0.002 0.225 9 3651.000 .991 .001 
Wilks’s lambda 0.998 0.224 9 2957.141 .991 .001 
Hotelling’s trace 0.002 0.224 9 3641.000 .991 .001 
  (table continues)     
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   df   
Effect and testa Value F Hypothesis Error p Partial η2 
 
Roy’s largest root 
0.001 0.496c 3 1217.000 .685 .001 
Location × Marital Status       
Pillai’s trace 0.004 0.588 9 3651.000 .808 .001 
Wilks’s lambda 0.996 0.588 9 2957.141 .808 .001 
Hotelling’s trace 0.004 0.588 9 3641.000 .808 .001 
Roy’s largest root 0.004 1.576c 3 1217.000 .193 .004 
Education × Marital Status       
Pillai’s trace 0.012 0.587 24 3651.000 .944 .004 
Wilks’s lambda 0.988 0.587 24 3524.471 .944 .004 
Hotelling’s trace 0.012 0.588 24 3641.000 .944 .004 
Roy’s largest root 0.010 1.449c 8 1217.000 .172 .009 
Location × Education × Marital Status       
Pillai’s trace 0.007 0.506 18 3651.000 .957 .002 
Wilks’s lambda 0.993 0.506 18 3437.024 .957 .002 
Hotelling’s trace 0.007 0.505 18 3641.000 .957 .002 
Roy’s largest root 0.005 1.039c 6 1217.000 .398 .005 
a. Design: Intercept + LOCATION + EDUCATION + MARITALST + LOCATION * EDUCATION + LOCATION * 
MARITALST + EDUCATION * MARITALST + LOCATION * EDUCATION * MARITALST 
b. Exact statistic 
c. The statistic is an upper bound on F that yields a lower bound on the significance level. 
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Hypothesis Testing 5 
The 5th hypothesis stated as follows: there is no statistically significant association 
between clinical determinants (government services, clinic services, NGO services) with 
HIV serostatus of Zambian female adolescents from ages 18 to 24. Tables 14, 15, and 16 
show the test results for hypothesis testing 5.  
The multivariate tests demonstrated no statistically significant associations 
between clinical determinants (government services, clinic services, NGO services) with 
HIV serostatus (see table 14). 
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Table 14 
 
Multivariate Tests on Clinical Determinants of HIV Serostatus for Zambian Women Aged 18–24 Years 
Effect and testa Value Fb p Partial η2 
Intercept     
Pillai’s trace 0.986 43,506.206 .000 .986 
Wilks’s lambda 0.014 43,506.206 .000 .986 
Hotelling’s trace 71.380 43,506.206 .000 .986 
Roy’s largest root 71.380 43,506.206 .000 .986 
Clinic services     
Pillai’s trace 0.000 0.170 .844 .000 
Wilks’s lambda 1.000 0.170 .844 .000 
Hotelling’s trace 0.000 0.170 .844 .000 
Roy’s largest root 0.000 0.170 .844 .000 
NGO Services     
Pillai’s trace 0.003 1.658 .191 .003 
Wilks’s lambda 0.997 1.658 .191 .003 
Hotelling’s trace 0.003 1.658 .191 .003 
Roy’s largest root 0.003 1.658 .191 .003 
Government services     
Pillai’s trace 0.000 0.287 .751 .000 
Wilks’s lambda 1.000 0.287 .751 .000 
Hotelling’s trace 0.000 0.287 .751 .000 
Roy’s largest root 0.000 0.287 .751 .000 
Clinic Services × NGO Services     
Pillai’s trace 0.000 0.002 .998 .000 
Wilks’s lambda 1.000 0.002 .998 .000 
Hotelling’s trace 0.000 0.002 .998 .000 
Roy’s largest root 0.000 0.002 .998 .000 
   (table continues)  
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Effect and testa Value Fb p Partial η2 
Clinic Services × Government Services     
Pillai’s trace 0.000 0.006 .994 .000 
Wilks’s lambda 1.000 0.006 .994 .000 
Hotelling’s trace 0.000 0.006 .994 .000 
Roy’s largest root 0.000 0.006 .994 .000 
NGO Services × Government Services     
Pillai’s trace 0.001 0.597 .551 .001 
Wilks’s lambda 0.999 0.597 .551 .001 
Hotelling’s trace 0.001 0.597 .551 .001 
Roy’s largest root 0.001 0.597 .551 .001 
Clinic Services × NGO Services × Government Services     
Pillai’s trace 0.000 0.089 .915 .000 
Wilks’s lambda 1.000 0.089 .915 .000 
Hotelling’s trace 0.000 0.089 .915 .000 
Roy’s largest root 0.000 0.089 .915 .000 
Note. Hypothesis df = 2. Error df = 1219. NGO = nongovernmental organization. 
a. Design: Intercept + GOVTEST + CLINICTEST + NGOTEST + GOVTEST * CLINICTEST + GOVTEST * 
NGOTEST + CLINICTEST * NGOTEST + GOVTEST * CLINICTEST * NGOTEST 
b. Exact statistic 
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Unlike the multivariate test (see table 14), Tukey’s Honestly Significant 
Difference (HSD) and Least Significant Difference (LSD) test in  table 15 reports  a 
statistically significant results for  the association between clinical determinants of an 
independent variable, use of services (yes, no, and N/A) and HIV serostatus as follows: 
1 Mean scores of HIV test result statistically significantly different between the 
yes and N/A conditions (p < .001) and the no and N/A conditions (p = .003). 
2. Mean scores of ever tested HIV were statistically significantly different 
between the yes and N/A conditions (p < .001) and between the no and N/A 
conditions (p < .001).
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Table 15 
 
Tukey’s Honestly Significant Difference (HSD) and Least Significant Difference (LSD) for Clinical Determinants of HIV 
Serostatus for Zambian Women Aged 18–24 Years 
   Tukey’s HSD  LSD 
Use of HIV services (I & J) Mean difference (I − J) SE p 
95% CI   95% CI 
LL UL  p LL UL 
Dependent variable: HIV test result 
Yes          
No −6.18 3.012 .100 −13.25 0.88  .040 −12.09 −0.28 
N/A −58.14 15.965 .001 −95.60 −20.67  .000 −89.46 −26.81 
No          
Yes 6.18 3.012 .100 −0.88 13.25  .040 0.28 12.09 
N/A −51.95 15.791 .003 −89.00 −14.90  .001 −82.93 −20.97 
N/A          
Yes 58.14 15.965 .001 20.67 95.60  .000 26.81 89.46 
No 51.95 15.791 .003 14.90 89.00  .001 20.97 82.93 
Dependent variable: ever tested HIV 
Yes          
No 0.00 0.002 .876 −0.01 0.00  .624 −0.01 0.00 
N/A −1.00 0.011 .000 −1.03 −0.97  .000 −1.02 −0.98 
No          
Yes 0.00 0.002 .876 0.00 0.01  .624 0.00 0.01 
N/A −1.00 0.011 .000 −1.02 −0.97  .000 −1.02 −0.98 
N/A          
Yes 1.00 0.011 .000 0.97 1.03  .000 0.98 1.02 
No 1.00 0.011 .000 0.97 1.02  .000 0.98 1.02 
Note. CI = confidence interval; LL = lower limit; UL = upper limit.  
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Tests of Between-Subjects Effects on Clinical Determinants of HIV Serostatus for 
Zambian Women Aged 18–24 indicated no statistically significant associations between 
clinical determinants and the HIV serostatus (see table 16). The clinical determinants 
allude to the use of HIV services GOV, the use of HIV services Clinic, and the use of 
HIV services NGO and the dependent variables.
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Table 16 
 
Tests of Between-Subjects Effects on Clinical Determinants of HIV Serostatus for Zambian Women Aged 18–24 Years 
Source and dependent variable 
Type III sum of 
squares df Mean square F p Partial η2 
Corrected model       
HIV test result 40,836.240a 8 5,104.530 2.945 .003 .019 
Ever tested HIV 6.949b 8 0.869 1,061.046 .000 .874 
Ever tested AIDS 6.960c 8 0.870 — — 1.000 
Intercept       
HIV test result 76,667.166 1 76,667.166 44.238 .000 .035 
Ever tested HIV 71.139 1 71.139 86,896.369 .000 .986 
Ever tested AIDS 71.126 1 71.126 — — 1.000 
Government services       
HIV test result 990.538 1 990.538 0.572 .450 .000 
Ever tested HIV 0.000 1 0.000 0.001 .972 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
Clinic services       
HIV test result 584.172 1 584.172 0.337 .562 .000 
Ever tested HIV 0.000 1 0.000 0.001 .972 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
NGO Services       
HIV test result 5,742.330 1 5,742.330 3.313 .069 .003 
Ever tested HIV 0.000 1 0.000 0.001 .972 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
Government Services × Clinic Services       
HIV test result 19.771 1 19.771 0.011 .915 .000 
Ever tested HIV 0.000 1 0.000 0.001 .972 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
      (table continues)  
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Source and dependent variable 
Type III sum of 
squares df Mean square F p Partial η2 
Government Services × NGO Services       
HIV test result 2,071.387 1 2,071.387 1.195 .274 .001 
Ever tested HIV 0.000 1 0.000 0.001 .972 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
Clinic Services × NGO Services       
HIV test result 4.953 1 4.953 0.003 .957 .000 
Ever tested HIV 0.000 1 0.000 0.001 .972 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
Government Services × Clinic Services × NGO Services       
HIV test result 306.166 1 306.166 0.177 .674 .000 
Ever tested HIV 0.000 1 0.000 0.001 .972 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
Error       
HIV test result 2,114,345.002 1220 1,733.070    
Ever tested HIV 0.999 1220 0.001    
Ever tested AIDS 0.000 1220 0.000    
Total       
HIV test result 3,673,895.000 1229     
Ever tested HIV 1,253.000 1229     
Ever tested AIDS 1,250.000 1229     
Corrected total       
HIV test result 2,155,181.242 1228     
Ever tested HIV 7.948 1228     
Ever tested AIDS 6.960 1228     
Note. NGO = nongovernmental organization. 
a. R Squared = .023 (Adjusted R Squared = .002) 
b. R Squared = 1.000 (Adjusted R Squared = 1.000) 
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Hypothesis Testing 6 
Multivariate analysis of variance was performed to test hypothesis 6 stated as 
follows: there is no statistically significant association between clinical determinants and 
that of HIV serostatus of Zambian female adults from age 25 to 49. Tables 17, 18, and 19 
validate hypothesis testing 6 for Zambian women aged 25–49 years. 
Table 17 reports on associations between clinical determinants and HIV serostatus 
for Zambian women aged 25 – 49. The results of the Tukey’s Honestly Significant 
Difference (HSD) and Least Significant Difference (LSD) for the use of services variable 
with three levels (yes, no, and N/A) are as follows: 
1. Mean scores of HIV test results were statistically significantly different 
between the yes and N/A conditions (p < .001) and between the N/A and no 
conditions (p < .001). 
2. Mean scores of ever tested HIV were statistically significantly different 
between the yes and N/A conditions (p < .001) and between the no and N/A 
conditions (p < .001)  (see table 17). 
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Table 17 
 
Tukey’s Honestly Significant Difference (HSD) and Least Significant Difference (LSD) for Clinical Determinants of HIV 
Serostatus for Zambian Women of Aged 25–49 Years 
   Tukey’s HSD  LSD 
Use of HIV services (I & J) Mean difference (I − J) SE p 
95% CI   95% CI 
LL UL  p LL UL 
Dependent variable: HIV test result 
Yes          
No −7.28 3.225 .063 −14.84 0.29  .024 −13.60 −0.95 
N/A −59.24 16.009 .001 −96.81 −21.67  .000 −90.65 −27.83 
No          
Yes 7.28 3.225 .063 −0.29 14.84  .024 0.95 13.60 
N/A −51.96 15.788 .003 −89.01 −14.92  .001 −82.94 −20.99 
N/A          
Yes 59.24 16.009 .001 21.67 96.81  .000 27.83 90.65 
No 51.96 15.788 .003 14.92 89.01  .001 20.99 82.94 
Dependent variable: ever tested HIV 
Yes          
No 0.00 0.002 .898 −0.01 0.00  .659 −0.01 0.00 
N/A −1.00 0.011 .000 −1.03 −0.97  .000 −1.02 −0.98 
No          
Yes 0.00 0.002 .898 0.00 0.01  .659 0.00 0.01 
N/A −1.00 0.011 .000 −1.02 −0.97  .000 −1.02 −0.98 
N/A          
Yes 1.00 0.011 .000 0.97 1.03  .000 0.98 1.02 
No 1.00 0.011 .000 0.97 1.02  .000 0.98 1.02 
Note. CI = confidence interval; LL = lower limit; UL = upper limit. 
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As shown in Table 18, there were no statistically significant differences between 
clinical determinants and a linear combination of the three dependent variables (HIV 
serostatus, ever tested HIV, ever tested AIDS) for adult Zambian women (25 - 49).
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Table 18 
 
Multivariate Tests on Clinical Determinants of HIV Serostatus for Zambian Women Aged 25–49 Years 
Effect and testa Value Fb p Partial η2 
Intercept     
Pillai’s trace 0.986 43,506.206 .000 .986 
Wilks’s lambda 0.014 43,506.206 .000 .986 
Hotelling’s trace 71.380 43,506.206 .000 .986 
Roy’s largest root 71.380 43,506.206 .000 .986 
Clinic services     
Pillai’s trace 0.000 0.170 .844 .000 
Wilks’s lambda 1.000 0.170 .844 .000 
Hotelling’s trace 0.000 0.170 .844 .000 
Roy’s largest root 0.000 0.170 .844 .000 
NGO Services     
Pillai’s trace 0.003 1.658 .191 .003 
Wilks’s lambda 0.997 1.658 .191 .003 
Hotelling’s trace 0.003 1.658 .191 .003 
Roy’s largest root 0.003 1.658 .191 .003 
Government services     
Pillai’s trace 0.000 0.287 .751 .000 
Wilks’s lambda 1.000 0.287 .751 .000 
Hotelling’s trace 0.000 0.287 .751 .000 
Roy’s largest root 0.000 0.287 .751 .000 
Clinic Services × NGO Services     
Pillai’s trace 0.000 0.002 .998 .000 
Wilks’s lambda 1.000 0.002 .998 .000 
Hotelling’s trace 0.000 0.002 .998 .000 
Roy’s largest root 0.000 0.002 .998 .000 
(table continues)  
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Effect and testa Value Fb p Partial η2 
Clinic Services × Government Services     
Pillai’s trace 0.000 0.006 .994 .000 
Wilks’s lambda 1.000 0.006 .994 .000 
Hotelling’s trace 0.000 0.006 .994 .000 
Roy’s largest root 0.000 0.006 .994 .000 
NGO Services × Government Services     
Pillai’s trace 0.001 0.597 .551 .001 
Wilks’s lambda 0.999 0.597 .551 .001 
Hotelling’s trace 0.001 0.597 .551 .001 
Roy’s largest root 0.001 0.597 .551 .001 
Clinic Services × NGO Services × Government Services     
Pillai’s trace 0.000 0.089 .915 .000 
Wilks’s lambda 1.000 0.089 .915 .000 
Hotelling’s trace 0.000 0.089 .915 .000 
Roy’s largest root 0.000 0.089 .915 .000 
Note. Hypothesis df = 2. Error df = 1219. NGO = nongovernmental organization. 
a. Design: Intercept + GOVTEST + CLINICTEST + NGOTEST + GOVTEST * CLINICTEST + GOVTEST * NGOTEST + 
CLINICTEST * NGOTEST + GOVTEST * CLINICTEST * NGOTEST 
b. Exact statistic 
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Tests of Between-Subjects Effects for Clinical Determinants of HIV Serostatus 
for Zambian women aged 25–49 demonstrate no statistically significant outcomes for the 
association between clinical determinants and the dependent variables (see table 19).
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Table 19 
 
Tests of Between-Subjects Effects for Clinical Determinants of HIV Serostatus for Zambian Women Aged 25–49 Years 
Source and dependent variable 
Type III sum of 
squares df Mean square F p Partial η2 
Corrected model       
HIV test result 40,836.240a 8 5,104.530 2.945 .003 .019 
Ever tested HIV 6.949b 8 0.869 1061.046 .000 .874 
Ever tested AIDS 6.960c 8 0.870 — — 1.000 
Intercept       
HIV test result 76,667.166 1 76,667.166 44.238 .000 .035 
Ever tested HIV 71.139 1 71.139 86896.369 .000 .986 
Ever tested AIDS 71.126 1 71.126 — — 1.000 
Clinic services       
HIV test result 584.172 1 584.172 0.337 .562 .000 
Ever tested HIV 0.000 1 0.000 0.001 .972 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
NGO Services       
HIV test result 5,742.330 1 5,742.330 3.313 .069 .003 
Ever tested HIV 0.000 1 0.000 0.001 .972 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
Government services       
HIV test result 990.538 1 990.538 0.572 .450 .000 
Ever tested HIV 0.000 1 0.000 0.001 .972 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
Clinic Services × NGO Services       
HIV test result 4.953 1 4.953 0.003 .957 .000 
Ever tested HIV 0.000 1 0.000 0.001 .972 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
(table continues)  
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Source and dependent variable 
Type III sum of 
squares df Mean square F p Partial η2 
Clinic Services × Government Services       
HIV test result 19.771 1 19.771 0.011 .915 .000 
Ever tested HIV 0.000 1 0.000 0.001 .972 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
NGO Services × Government Services       
HIV test result 2,071.387 1 2,071.387 1.195 .274 .001 
Ever tested HIV 0.000 1 0.000 0.001 .972 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
Clinic Services × NGO Services × Government Services       
HIV test result 306.166 1 306.166 0.177 .674 .000 
Ever tested HIV 0.000 1 0.000 0.001 .972 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
Error       
HIV test result 2,114,345.002 1220 1,733.070    
Ever tested HIV 0.999 1220 0.001    
Ever tested AIDS 0.000 1220 0.000    
Total       
HIV test result 3,673,895.000 1229     
Ever tested HIV 1253.000 1229     
Ever tested AIDS 1250.000 1229     
Corrected total       
HIV test result 2,155,181.242 1228     
Ever tested HIV 7.948 1228     
Ever tested AIDS 6.960 1228     
Note. NGO = nongovernmental organization. 
a. R Squared = .024 (Adjusted R Squared = .016) 
b. R Squared = .799 (Adjusted R Squared = .797) 
c. R Squared = 1.000 (Adjusted R Squared = 1.000)  
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Hypothesis Testing 7 
Multivariate analysis of variance was also performed to test hypothesis 7 stated as 
follows: there is no statistically significant synergistic association between behavioral, 
demographic, and clinical determinants and that of HIV serostatus of Zambian female 
adolescents from age 18 to 24. Tables 20, 21, 22,  and 23 show the test results for 
hypothesis testing 7. The synergistic associations between sexual partners, location, and 
government with HIV test results were not statistically significant, leading to failing to 
reject hypothesis testing 7 (see table 20).  
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Table 20 
 
Multivariate Tests on Synergistic Analysis of Behavioral, Demographic, and Clinical Determinants of HIV Serostatus for 
Zambian Women Aged 18–24 Years 
   df   
Effect and testa Value F Hypothesis Error p Partial η2 
Intercept       
Pillai’s trace 0.991 63,188.837b 2 1195.0 .000 .991 
Wilks’s lambda 0.009 63,188.837b 2 1195.0 .000 .991 
Hotelling’s trace 105.755 63,188.837b 2 1195.0 .000 .991 
Roy’s largest root 105.755 63,188.837b 2 1195.0 .000 .991 
Sexual partners       
Pillai’s trace 0.001 0.257 4 2392.0 .905 .000 
Wilks’s lambda 0.999 0.257b 4 2390.0 .905 .000 
Hotelling’s trace 0.001 0.257 4 2388.0 .905 .000 
Roy’s largest root 0.001 0.508c 2 1196.0 .602 .001 
Location       
Pillai’s trace 0.001 0.438b 2 1195.0 .645 .001 
Wilks’s lambda 0.999 0.438b 2 1195.0 .645 .001 
Hotelling’s trace 0.001 0.438b 2 1195.0 .645 .001 
Roy’s largest root 0.001 0.438b 2 1195.0 .645 .001 
Government services       
Pillai’s trace 0.870 460.457 4 2392.0 .000 .435 
Wilks’s lambda 0.130 1,058.488b 4 2390.0 .000 .639 
Hotelling’s trace 6.680 1,993.840 4 2388.0 .000 .770 
Roy’s largest root 6.679 3,994.196c 2 1196.0 .000 .870 
Sexual Partners × Location       
Pillai’s trace 0.004 1.285 4 2392.0 .273 .002 
(table continues)       
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   df   
Effect and testa Value F Hypothesis Error p Partial η2 
 
Wilks’s lambda 
0.996 1.285b 4 2390.0 .273 .002 
Hotelling’s trace 0.004 1.285 4 2388.0 .273 .002 
Roy’s largest root 0.004 2.471c 2 1196.0 .085 .004 
Sexual Partners × Government Services       
Pillai’s trace 0.001 0.416b 2 1195.0 .660 .001 
Wilks’s lambda 0.999 0.416b 2 1195.0 .660 .001 
Hotelling’s trace 0.001 0.416b 2 1195.0 .660 .001 
Roy’s largest root 0.001 0.416b 2 1195.0 .660 .001 
Location × Government Services       
Pillai’s trace 0.000 0.039 4 2392.0 .997 .000 
Wilks’s lambda 1.000 0.038b 4 2390.0 .997 .000 
Hotelling’s trace 0.000 0.038 4 2388.0 .997 .000 
Roy’s largest root 0.000 0.077c 2 1196.0 .926 .000 
Sexual Partners × Location × Government Services       
Pillai’s trace 0.000 —b 0 0.0 — — 
Wilks’s lambda 1.000 —b 0 1195.5 — — 
Hotelling’s trace 0.000 —b 0 2.0 — — 
Roy’s largest root 0.000 0.000b 2 1194.0 1.000 .000 
a. Design: Intercept + SEXPARTN + LOCATION + GOVTEST + SEXPARTN * LOCATION + SEXPARTN * GOVTEST + 
LOCATION * GOVTEST + SEXPARTN * LOCATION * GOVTEST 
b. Exact statistic 
c. The statistic is an upper bound on F that yields a lower bound on the significance level. 
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Tests of Between-Subjects Effects on Synergistic Analysis of Behavioral, 
Demographic, and Clinical Determinants of HIV Serostatus for Zambian Women Aged 
18–24 demonstrated no statistically significant association between government services 
(clinical determinant) and location (demographic determinant) with HIV test result 
(dependent variable) (see table 21). The research failed to reject the null hypothesis that 
stated there is no statistically significant synergistic association between behavioral, 
demographic, and clinical determinants and that of HIV serostatus of Zambian female 
adolescents from age 18 to 24 (see table 21). 
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Table 21 
 
Tests of Between-Subjects Effects on Synergistic Analysis of Behavioral, Demographic, and Clinical Determinants of HIV 
Serostatus for Zambian Women Aged 18–24 Years 
Source and dependent variable 
Type III sum of 
squares df Mean square F p Partial η2 
Corrected model       
HIV test result 34,498.711a 10 3,449.871 1.976 .033 .016 
Ever tested HIV 6.957b 10 0.696 840.657 .000 .875 
Ever tested AIDS 6.959c 10 0.696 — — 1.000 
Intercept       
HIV test result 160,018.881 1 160,018.881 91.663 .000 .071 
Ever tested HIV 104.444 1 104.444 126,203.238 .000 .991 
Ever tested AIDS 104.376 1 104.376 — — 1.000 
Sexual partners       
HIV test result 966.880 2 483.440 0.277 .758 .000 
Ever tested HIV 0.000 2 0.000 0.228 .796 .000 
Ever tested AIDS 0.000 2 0.000 — — — 
Location       
HIV test result 1,286.787 1 1,286.787 0.737 .391 .001 
Ever tested HIV 0.000 1 0.000 0.153 .695 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
Government services       
HIV serostatus test 19,569.150 2 9,784.575 5.605 .004 .009 
HIV test result 6.590 2 3.295 3,981.198 .000 .869 
Ever tested AIDS 6.603 2 3.301 — — 1.000 
Sexual Partners × Location       
HIV test result 749.435 2 374.717 0.215 .807 .000 
Ever tested HIV 0.004 2 0.002 2.380 .093 .004 
(table continues)  
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Source and dependent variable 
Type III sum of 
squares df Mean square F p Partial η2 
Ever tested AIDS 0.000 2 0.000 — — — 
Sexual Partners × Government Services       
HIV test result 400.014 1 400.014 0.229 .632 .000 
Ever tested HIV 0.001 1 0.001 0.619 .431 .001 
Ever tested AIDS 0.000 1 0.000 — — — 
Location × Government Services       
HIV test result 268.757 2 134.378 0.077 .926 .000 
Ever tested HIV 0.000 2 0.000 0.000 1.000 .000 
Ever tested AIDS 0.000 2 0.000 — — — 
Sexual Partners × Location × Government Services       
HIV test result 0.000 0 — — — .000 
Ever tested HIV 0.000 0 — — — .000 
Ever tested AIDS 0.000 0 — — — — 
Error       
HIV test result 2,087,891.405 1196 1,745.729    
Ever tested HIV 0.990 1196 0.001    
Ever tested AIDS 0.000 1196 0.000    
Total       
HIV test result 3,635,110.000 1207     
Ever tested HIV 1,231.000 1207     
Ever tested AIDS 1,228.000 1207     
Corrected total       
HIV test result 2,122,390.116 1206     
Ever tested HIV 7.947 1206     
Ever tested AIDS 6.959 1206     
a. R Squared = .041 (Adjusted R Squared = .023) 
b. R Squared = .876 (Adjusted R Squared = .874) c. R Squared = 1.000 (Adjusted R Squared = 1.000) 
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Table 22 shows the results of multivariate tests on associations between 
synergistic combinations of the behavioral determinant (condom use) demographic 
determinant (education), and clinical determinant (clinic services) with the dependent 
variables. Those tests lacked statistically significant associations between the combined 
effect of the independent variables and the dependent variables (see table 22). 
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Table 222 
 
Multivariate Tests on Synergistic Analysis of Behavioral, Demographic, and Clinical Determinants of HIV Serostatus for 
Zambian Women Aged 18–24 Years 
   df   
Effect and testa Value F Hypothesis Error p Partial η2 
Intercept       
Pillai’s trace 0.987 43,460.100b 2 1183 .000 .987 
Wilks’s lambda 0.013 43,460.100b 2 1183 .000 .987 
Hotelling’s trace 73.474 43,460.100b 2 1183 .000 .987 
Roy’s largest root 73.474 43,460.100b 2 1183 .000 .987 
Condom use       
Pillai’s trace 0.000 0.115 4 2368 .977 .000 
Wilks’s lambda 1.000 0.115b 4 2366 .977 .000 
Hotelling’s trace 0.000 0.115 4 2364 .977 .000 
Roy’s largest root 0.000 0.158c 2 1184 .854 .000 
Education       
Pillai’s trace 0.008 1.527 6 2368 .165 .004 
Wilks’s lambda 0.992 1.528b 6 2366 .165 .004 
Hotelling’s trace 0.008 1.530 6 2364 .164 .004 
Roy’s largest root 0.008 3.038c 3 1184 .028 .008 
Clinic services       
Pillai’s trace 0.776 375.283 4 2368 .000 .388 
Wilks’s lambda 0.224 658.140b 4 2366 .000 .527 
Hotelling’s trace 3.463 1,023.418 4 2364 .000 .634 
Roy’s largest root 3.463 2,050.299c 2 1184 .000 .776 
Condom Use × Education       
Pillai’s trace 0.003 0.281 12 2368 .992 .001 
(table continues)  
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   df   
Effect and testa Value F Hypothesis Error p Partial η2 
Wilks’s lambda 0.997 0.280b 12 2366 .992 .001 
Hotelling’s trace 0.003 0.280 12 2364 .992 .001 
Roy’s largest root 0.002 0.368c 6 1184 .899 .002 
Condom Use × Clinic Services       
Pillai’s trace 0.001 0.172 4 2368 .953 .000 
Wilks’s lambda 0.999 0.172b 4 2366 .953 .000 
Hotelling’s trace 0.001 0.172 4 2364 .953 .000 
Roy’s largest root 0.000 0.257c 2 1184 .774 .000 
Education × Clinic Services       
Pillai’s trace 0.002 0.347 8 2368 .947 .001 
Wilks’s lambda 0.998 0.347b 8 2366 .947 .001 
Hotelling’s trace 0.002 0.347 8 2364 .948 .001 
Roy’s largest root 0.002 0.446c 4 1184 .775 .002 
Condom Use × Education × Clinic Services       
Pillai’s trace 0.002 0.476 6 2368 .826 .001 
Wilks’s lambda 0.998 0.476b 6 2366 .826 .001 
Hotelling’s trace 0.002 0.476 6 2364 .827 .001 
Roy’s largest root 0.002 0.739c 3 1184 .529 .002 
a. Design: Intercept + CONDOUSE + EDUCATION + CLINICTEST + CONDOUSE * EDUCATION + CONDOUSE * 
CLINICTEST + EDUCATION * CLINICTEST + CONDOUSE * EDUCATION * CLINICTEST 
b. Exact statistic 
c. The statistic is an upper bound on F that yields a lower bound on the significance level. 
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Tests of Between-Subjects Effects on Synergistic Association of Behavioral 
(condom use), Demographic (education), and Clinical (clinic service) Determinants with  
HIV Serostatus for Zambian Women Aged 18–24 was not statistically significant (see 
table 23).    
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Table 233 
 
Tests of Between-Subjects Effects on Synergistic Association of Behavioral, Demographic, and Clinical Determinants of HIV 
Serostatus for Zambian Women Aged 18–24 Years 
Source and dependent variable Type III sum of squares df Mean square F p Partial η2 
Corrected model       
HIV test result 86,213.651a 22 3,918.802 2.279 .001 .041 
Ever tested HIV 6.961b 22 0.316 379.814 .000 .876 
Ever tested AIDS 6.959c 22 0.316 — — 1.000 
Intercept       
HIV test result 86,864.115 1 86,864.115 50.510 .000 .041 
Ever tested HIV 72.287 1 72.287 86,776.980 .000 .987 
Ever tested AIDS 72.206 1 72.206 — — 1.000 
Condom use       
HIV test result 501.097 2 250.548 0.146 .864 .000 
Ever tested HIV 0.000 2 0.000 0.086 .918 .000 
Ever tested AIDS 0.000 2 0.000 — — — 
Education       
HIV test result 15,671.279 3 5,223.760 3.038 .028 .008 
Ever tested HIV 0.000 3 0.000 0.029 .993 .000 
Ever tested AIDS 0.000 3 0.000 — — — 
Clinic services       
HIV test result 10,211.055 2 5,105.527 2.969 .052 .005 
Ever tested HIV 3.402 2 1.701 2,041.941 .000 .775 
Ever tested AIDS 3.402 2 1.701 — — 1.000 
Condom Use × Education       
HIV test result 2,855.722 6 475.954 0.277 .948 .001 
Ever tested HIV 0.001 6 0.000 0.289 .942 .001 
(table continues)  
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Source and dependent variable Type III sum of squares df Mean square F p Partial η2 
Ever tested AIDS 0.000 6 0.000 — — — 
Condom Use × Clinic Services       
HIV test result 494.468 2 247.234 0.144 .866 .000 
Ever tested HIV 0.000 2 0.000 0.196 .822 .000 
Ever tested AIDS 0.000 2 0.000 — — — 
Education × Clinic Services       
HIV test result 2,362.905 4 590.726 0.343 .849 .001 
Ever tested HIV 0.001 4 0.000 0.356 .840 .001 
Ever tested AIDS 0.000 4 0.000 — — — 
Condom Use × Education × Clinic Services       
HIV test result 2,398.792 3 799.597 0.465 .707 .001 
Ever tested HIV 0.001 3 0.000 0.475 .700 .001 
Ever tested AIDS 0.000 3 0.000 — — — 
Error       
HIV test result 2,036,176.465 1184 1,719.744    
Ever tested HIV 0.986 1184 0.001    
Ever tested AIDS 0.000 1184 0.000    
Total       
HIV test result 3,635,110.000 1207     
Ever tested HIV 1,231.000 1207     
Ever tested AIDS 1,228.000 1207     
Corrected total       
HIV test result 2,122,390.116 1206     
Ever tested HIV 7.947 1206     
Ever tested AIDS 6.959 1206     
a. R Squared = .041 (Adjusted R Squared = .023) 
b. R Squared = .876 (Adjusted R Squared = .874) 
c. R Squared = 1.000 (Adjusted R Squared = 1.000) 
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Hypothesis Testing 8 
Tables 24, 25, 26, and 27 present MANOVA results to test hypothesis testing 8. 
Multivariate analysis of variance (MANOVA) was also performed to test hypothesis 8 
stated as follows: there is no statistically significant synergistic association between 
behavioral, demographic, and clinical determinants and that of the HIV test result of 
Zambian female adults from age 25 to 49 (see table 24).  The researcher failed to accept 
the null hypothesis. 
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Table 244 
 
Tests of Between-Subjects Effects on Synergistic Analysis of Behavioral, Demographic, and Clinical Determinants of HIV 
Serostatus for Zambian Women Aged 25–49 
Source and dependent variable 
Type III sum of 
squares df Mean square F p Partial η2 
Corrected model       
HIV test result 34,498.711a 10 3,449.871 1.976 .033 .016 
Ever tested HIV 6.957b 10 0.696 840.657 .000 .875 
Ever tested AIDS 6.959c 10 0.696 — — 1.000 
Intercept       
HIV test result 160,018.881 1 160,018.881 91.663 .000 .071 
Ever tested HIV 104.444 1 104.444 126,203.238 .000 .991 
Ever tested AIDS 104.376 1 104.376 — — 1.000 
Sexual partners       
HIV test result 966.880 2 483.440 0.277 .758 .000 
Ever tested HIV 0.000 2 0.000 0.228 .796 .000 
Ever tested AIDS 0.000 2 0.000 — — — 
Location       
HIV test result 1,286.787 1 1,286.787 0.737 .391 .001 
Ever tested HIV 0.000 1 0.000 0.153 .695 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
Government services       
HIV test result 19,569.150 2 9,784.575 5.605 .004 .009 
Ever tested HIV 6.590 2 3.295 3,981.198 .000 .869 
Ever tested AIDS 6.603 2 3.301 — — 1.000 
Sexual Partners × Location       
HIV test result 749.435 2 374.717 0.215 .807 .000 
Ever tested HIV 0.004 2 0.002 2.380 .093 .004 
(table continues)  
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Source and dependent variable 
Type III sum of 
squares df Mean square F p Partial η2 
Ever tested AIDS 0.000 2 0.000 — — — 
Sexual Partners × Government Services       
HIV test result 400.014 1 400.014 0.229 .632 .000 
Ever tested HIV 0.001 1 0.001 0.619 .431 .001 
Ever tested AIDS 0.000 1 0.000 — — — 
Location × Government Services       
HIV test result 268.757 2 134.378 0.077 .926 .000 
Ever tested HIV 0.000 2 0.000 0.000 1.000 .000 
Ever tested AIDS 0.000 2 0.000 — — — 
Sexual Partners × Location × Government Services       
HIV test result 0.000 0 — — — .000 
Ever tested HIV 0.000 0 — — — .000 
Ever tested AIDS 0.000 0 — — — — 
Error       
HIV test result 2,087,891.405 1196 1,745.729    
Ever tested HIV 0.990 1196 0.001    
Ever tested AIDS 0.000 1196 0.000    
Total       
HIV test result 3,635,110.000 1207     
Ever tested HIV 1,231.000 1207     
Ever tested AIDS 1,228.000 1207     
Corrected total       
HIV test result 2,122,390.116 1206     
Ever tested HIV 7.947 1206     
Ever tested AIDS 6.959 1206     
a. R Squared = .016 (Adjusted R Squared = .008)  
b. R Squared = .875 (Adjusted R Squared = .874)  c. R Squared = 1.000 R Squared = 1.000) 
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Tests of Between-Subjects Effects indicate no statistically significant association 
between the Synergistic associations of Behavioral (sexual partners, condom use, HIV 
self-perceived risk), demographic (education, location, marital status), and Clinical ( use 
of HIV services GOV, use of HIV services Clinic, use of HIV services NGO) 
determinants of HIV Serostatus for Zambian women aged 25–49 (see table 25). 
Therefore, the researcher failed to accept the null hypothesis stated as: there is no 
statistically significant synergistic association between behavioral, demographic, and 
clinical determinants and that of HIV serostatus of Zambian female adults from age 25 to 
49.  
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Table 255 
 
Tests of Between-Subjects Effects on Synergistic Association of Behavioral, Demographic, and Clinical Determinants of HIV 
Serostatus for Zambian Women Aged 25–49 Years 
Source and dependent variable Type III sum of squares df Mean square F p Partial η2 
Corrected model       
HIV test result 86,213.651a 22 3,918.802 2.279 .001 .041 
Ever tested HIV 6.961b 22 0.316 379.814 .000 .876 
Ever tested AIDS 6.959c 22 0.316 — — 1.000 
Intercept       
HIV test result 86,864.115 1 86,864.115 50.510 .000 .041 
Ever tested HIV 72.287 1 72.287 86,776.980 .000 .987 
Ever tested AIDS 72.206 1 72.206 — — 1.000 
Condom use       
HIV test result 501.097 2 250.548 0.146 .864 .000 
Ever tested HIV 0.000 2 0.000 0.086 .918 .000 
Ever tested AIDS 0.000 2 0.000 — — — 
Education       
HIV test result 15,671.279 3 5,223.760 3.038 .028 .008 
Ever tested HIV 0.000 3 0.000 0.029 .993 .000 
Ever tested AIDS 0.000 3 0.000 — — — 
Clinic services       
HIV test result 10,211.055 2 5,105.527 2.969 .052 .005 
Ever tested HIV 3.402 2 1.701 2,041.941 .000 .775 
Ever tested AIDS 3.402 2 1.701 — — 1.000 
Condom Use × Education       
HIV test result 2,855.722 6 475.954 0.277 .948 .001 
Ever tested HIV 0.001 6 0.000 0.289 .942 .001 
Ever tested AIDS 0.000 6 0.000 — — — 
    (table continues)  
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Source and dependent variable Type III sum of squares df Mean square F p Partial η2 
Condom Use × Clinic Services       
HIV test result 494.468 2 247.234 0.144 .866 .000 
Ever tested HIV 0.000 2 0.000 0.196 .822 .000 
Ever tested AIDS 0.000 2 0.000 — — — 
Education × Clinic Services       
HIV test result 2,362.905 4 590.726 0.343 .849 .001 
Ever tested HIV 0.001 4 0.000 0.356 .840 .001 
Ever tested AIDS 0.000 4 0.000 — — — 
Condom Use × Education × Clinic Services       
HIV test result 2,398.792 3 799.597 0.465 .707 .001 
Ever tested HIV 0.001 3 0.000 0.475 .700 .001 
Ever tested AIDS 0.000 3 0.000 — — — 
Error       
HIV test result 2,036,176.465 1184 1,719.744    
Ever tested HIV 0.986 1184 0.001    
Ever tested AIDS 0.000 1184 0.000    
Total       
HIV test result 3,635,110.000 1207     
Ever tested HIV 1,231.000 1207     
Ever tested AIDS 1,228.000 1207     
Corrected total       
HIV test result 2,122,390.116 1206     
Ever tested HIV 7.947 1206     
Ever tested AIDS 6.959 1206     
a. R Squared = .041 (Adjusted R Squared = .023) 
b. R Squared = .876 (Adjusted R Squared = .874)  
c. R Squared = 1.000 (Adjusted R Squared = 1.000) 
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Table 26 indicates that there were no statistically significant associations between 
the synergistic combination of the behavioral, demographic, and clinical variables self-
perceived HIV risk, marital status, and NGO services and the dependent variables for 
Zambian women aged 25–49 years. The researcher failed to reject the null hypothesis, 
stated as: there is no statistically significant synergistic association between behavioral, 
demographic, and clinical determinants and that of HIV serostatus of Zambian female 
adults from age 25 to 49.  
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Table 26 
 
Multivariate Tests on Synergistic Association of Behavioral, Demographic, and Clinical Determinants of HIV Serostatus for 
Zambian Women Aged 25–49 Years 
   df   
Effect and testa Value F Hypothesis Error p Partial η2 
Intercept       
Pillai’s trace 0.987 43575.177b 2 1183 .000 .987 
Wilks’s lambda 0.013 43575.177b 2 1183 .000 .987 
Hotelling’s trace 73.669 43575.177b 2 1183 .000 .987 
Roy’s largest root 73.669 43575.177b 2 1183 .000 .987 
Self-perceived HIV risk       
Pillai’s trace 0.011 1.292 10 2368 .229 .005 
Wilks’s lambda 0.989 1.294b 10 2366 .228 .005 
Hotelling’s trace 0.011 1.297 10 2364 .226 .005 
Roy’s largest root 0.011 2.597c 5 1184 .024 .011 
Marital status       
Pillai’s trace 0.000 0.051 6 2368 .999 .000 
Wilks’s lambda 1.000 0.051b 6 2366 .999 .000 
Hotelling’s trace 0.000 0.051 6 2364 .999 .000 
Roy’s largest root 0.000 0.102c 3 1184 .959 .000 
NGO Services       
Pillai’s trace 0.001 0.552b 2 1183 .576 .001 
Wilks’s lambda 0.999 0.552b 2 1183 .576 .001 
Hotelling’s trace 0.001 0.552b 2 1183 .576 .001 
Roy’s largest root 0.001 0.552b 2 1183 .576 .001 
Self-Perceived HIV Risk × Marital Status       
Pillai’s trace 0.008 0.329 28 2368 1.000 .004 
Wilks’s lambda 0.992 0.329b 28 2366 1.000 .004 
(table continues)  
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   df   
Effect and testa Value F Hypothesis Error p Partial η2 
Hotelling’s trace 0.008 0.329 28 2364 1.000 .004 
Roy’s largest root 0.008 0.657c 14 1184 .817 .008 
Self-Perceived HIV Risk × NGO Services       
Pillai’s trace 0.002 0.186 10 2368 .997 .001 
Wilks’s lambda 0.998 0.186b 10 2366 .997 .001 
Hotelling’s trace 0.002 0.186 10 2364 .997 .001 
Roy’s largest root 0.002 0.370c 5 1184 .869 .002 
Marital Status × NGO Services       
Pillai’s trace 0.002 0.333 6 2368 .920 .001 
Wilks’s lambda 0.998 0.333b 6 2366 .920 .001 
Hotelling’s trace 0.002 0.333 6 2364 .920 .001 
Roy’s largest root 0.002 0.665c 3 1184 .574 .002 
Self-Perceived HIV Risk × Marital Status × NGO Services       
Pillai’s trace 0.002 0.264 10 2368 .989 .001 
Wilks’s lambda 0.998 0.264b 10 2366 .989 .001 
Hotelling’s trace 0.002 0.264 10 2364 .989 .001 
Roy’s largest root 0.002 0.527c 5 1184 .756 .002 
Note. NGO = nongovernmental organization. 
a. Design: Intercept + CONDOUSE + EDUCATION + CLINICTEST + CONDOUSE * EDUCATION + CONDOUSE * 
CLINICTEST + EDUCATION * CLINICTEST + CONDOUSE * EDUCATION * CLINICTEST 
b. Exact statistic 
c. The statistic is an upper bound on F that yields a lower bound on the significance level. 
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Tests between Subjects Effects indicate no statistically significant synergistic 
associations between behavioral, demographic, and clinical determinants with HIV 
serostatus for Zambian women aged 25–49 years (see table 27). I failed to reject the null 
hypothesis, stated as: there is no statistically significant synergistic association between 
behavioral, demographic, and clinical determinants and that of HIV serostatus of 
Zambian female adults from age 25 to 49. 
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Table 27 
 
Tests of Between-Subjects Effects for Synergistic Association of Behavioral, Demographic, and Clinical Determinants of HIV 
Serostatus for Zambian Women Aged 25-49 Years 
Source and dependent variable 
Type III sum 
of squares df Mean square F p Partial η2 
Corrected model       
HIV test result 150,999.243a 38 3,973.664 2.357 .000 .070 
Ever tested HIV 6.950b 38 0.183 217.110 .000 .874 
Ever tested AIDS 6.960c 38 0.183 — — 1.000 
Intercept       
HIV test result 69,307.004 1 69,307.004 41.114 .000 .034 
Ever tested HIV 73.285 1 73.285 86991.580 .000 .987 
Ever tested AIDS 73.280 1 73.280 — — 1.000 
Self-perceived HIV risk       
HIV test result 21,857.469 5 4,371.494 2.593 .024 .011 
Ever tested HIV 0.000 5 0.000 0.001 1.000 .000 
Ever tested AIDS 0.000 5 0.000 — — — 
Marital status       
HIV test result 514.632 3 171.544 0.102 .959 .000 
Ever tested HIV 0.000 3 0.000 0.000 1.000 .000 
Ever tested AIDS 0.000 3 0.000 — — — 
NGO Services       
HIV test result 1,860.719 1 1,860.719 1.104 .294 .001 
Ever tested HIV 0.000 1 0.000 0.000 .991 .000 
Ever tested AIDS 0.000 1 0.000 — — — 
Self-Perceived HIV Risk × Marital Status       
HIV test result 15,497.342 14 1,106.953 0.657 .818 .008 
Ever tested HIV 0.000 14 0.000 0.003 1.000 .000 
(table continues)  
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Source and dependent variable 
Type III sum 
of squares df Mean square F p Partial η2 
Ever tested AIDS 0.000 14 0.000 — — — 
Self-Perceived HIV Risk × NGO Services       
HIV test result 3,121.318 5 624.264 0.370 .869 .002 
Ever tested HIV 0.000 5 0.000 0.002 1.000 .000 
Ever tested AIDS 0.000 5 0.000 — — — 
Marital Status × NGO Services       
HIV test result 3,358.103 3 1,119.368 0.664 .574 .002 
Ever tested HIV 0.000 3 0.000 0.002 1.000 .000 
Ever tested AIDS 0.000 3 0.000 — — — 
Self-Perceived HIV Risk × Marital Status × NGO Services       
HIV test result 4,404.772 5 880.954 0.523 .759 .002 
Ever tested HIV 0.000 5 0.000 0.004 1.000 .000 
Ever tested AIDS 0.000 5 0.000 — — — 
Error       
HIV test result 1,995,883.167 1184 1,685.712    
Ever tested HIV 0.997 1184 0.001    
Ever tested AIDS 0.000 1184 0.000    
Total       
HIV test result 3,666,131.000 1223     
Ever tested HIV 1247.000 1223     
Ever tested AIDS 1244.000 1223     
Corrected total       
HIV test result 2,146,882.410 1222     
Ever tested HIV 7.948 1222     
Ever tested AIDS 6.960 1222     
Note. NGO = nongovernmental organization. 
a. R Squared = .041 (Adjusted R Squared = .023) 
b. R Squared = .876 (Adjusted R Squared = .874)  c. R Squared = 1.000 (Adjusted R Squared = 1.000) 
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Summary 
This section summarizes the results of the MANOVA for each research question. 
Research Question 1 
The results showed a statistically significant association between HIV serostatus 
and the sexual partners' behavioral determinant for Zambian women aged 18–24. They 
also showed no significant association between HIV serostatus and the other two 
behavioral determinants (condom use and self-perceived HIV risk). 
Research Question 2 
The results for women aged 25–49 years showed a significant association 
between HIV serostatus and self-perceived HIV risk and no association between HIV 
serostatus and the other behavioral determinants (sexual partners and condom use). 
Research Question 3 
The results showed a statistically significant association between education and 
HIV serostatus among Zambian women aged 18–24 years. Unlike in previous studies, I 
found no statistically significant differences for the demographic variables’ location and 
marital status or pairwise interactions of location and marital status, location and 
education, or marital status and education. 
Research Question 4 
The results also indicated a statistically significant association between education 
and HIV serostatus among Zambian women aged 25–49 years. As with the results of 
Research Question 3, I found no statistically significant differences for the demographic 
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variables location and marital status or pairwise interactions of location and marital 
status, location and education, or marital status and education. 
Research Question 5 
MANOVA pairwise comparisons of clinical determinants indicated statistically 
significant variations among HIV services. Aggregate use of HIV services was associated 
with HIV serostatus for Zambian women aged 18–24 years. However, the use of 
government HIV services, clinic services, and NGO services were not individually 
associated with HIV serostatus among this age group. 
Research Question 6 
The results for women aged 25–49 were similar to those for women aged 18–24 
concerning the use of HIV services. There was a statistical association between aggregate 
use of services and HIV serostatus, but there were no associations between the use of 
government services, clinic services, or NGO services individually and HIV serostatus. 
Research Question 7 
Multivariate tests indicate no statistically significant synergistic association 
between behavioral, demographic, and clinical determinants of HIV serostatus for 
adolescent (18 -24 ) Zambian women.  
Research Question 8 
Multivariate tests show no statistically significant outcomes for the synergistic 
associations between behavioral and demographic determinants with HIV serostatus for 
Zambian women aged 25–49 years.  
Chapter 5 presents detailed discussions, conclusions, and recommendations  
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based on the results regarding associations between behavioral, demographic, and clinical 
determinants and HIV serostatus for Zambian women. 
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Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of the study was to determine the association between the 
demographic, behavioral, and clinical determinants and HIV serostatus in Zambian 
adolescents (aged 18–24 years) and adult (aged 25–49 years) women. I tested the 
hypotheses in the study using MANOVA. 
Interpretation of the Findings 
The findings of this study converged with those of existing studies in some ways 
and diverged from them in other ways. 
Behavioral Determinants of HIV Serostatus 
For both women aged 18–24 years and women aged 25–49 years, there was a 
significant association between HIV serostatus and self-perceived HIV risk but not sexual 
partners or condom use. This finding is partly consistent with Adeniyi et al. (2017), who 
also examined behavioral, demographic, and clinical determinants and HIV serostatus. 
However, Adeniyi et al. (2017) studied only one HIV serostatus variable compared to this 
study’s three serostatus variables. They also found a significant association of sexual 
behavior and the use of clinical services with HIV serostatus disclosure. 
The findings indicate a link between the HIV test result variable and self-
perceived HIV risk for women aged 18–24 years. There was a strong association between 
the perception of no risk or small risk and HIV serostatus. Toska et al. (2017) reported 
the presence of a direct association between HIV acquisition of adolescent women (aged 
18–24 years) and having multiple sexual partners, although the finding was inconclusive. 
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That finding was in harmony with a secondary analysis of a cross-sectional study 
conducted in Uganda, which indicated an association between self-perceived HIV risk 
and incidence of HIV infection among women of all ages. This study elucidates the 
impact of self-perceived HIV risk. It suggests a prevention strategy for Zambian women 
and also probably women in similar settings and socioeconomic statuses in other parts of 
sub-Saharan Africa. Rosenberg et al. (2017), reporting on a population-based study, said 
that the spread of HIV had accelerated in older adults in South Africa and recommended 
the commencement of prevention activities for analogous communities in sub-Saharan 
African countries. 
Demographic Determinants of HIV Serostatus 
The findings indicated a statistically significant association between education 
and HIV serostatus among women in both age groups. However, unlike previous studies, 
there were no statistically significant differences for the demographic variables of 
location and marital status and pairwise interactions of location and marital status, 
location and education, and marital status and education. Omonaiye, Kusljic, Nicholson, 
and Manias (2018), Pinchoff, Boyer, Mutombo, Chowdhuri, and Ngo (2017), and Okawa 
et al. (2018) reported that age and education were critical to determining HIV serostatus 
for adolescent and adult women at individual and societal levels. 
Lack of associations between HIV serostatus and age (adolescent versus adult) 
and location (urban versus rural) also contrasted with the findings of authors who stated 
strong and significant associations between HIV serostatus and age, gender, and location 
(Chanda-Kapata et al., 2016; McCarraher et al., 2018). Mee et al. (2018) found that being 
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in school increased students’ awareness of HIV and the practice of preventive measures 
and eventually contributed to the diminishing of the spread of HIV infection. 
Other researchers failed to find an association between education and the use of 
HIV services (Sabapathy et al., 2018). Bunyasi and Coetzee (2017) suggested a direct 
association between accomplishment in education and the reduction of HIV prevalence. It 
is possible that the main reason for the association between lower incidence of HIV and 
higher educational achievement is the ability of educated people to implement safer 
sexual practices and abstain from sexual activity. Increased health literacy and academic 
progress could empower educated people to make informed decisions and take 
responsibility for themselves and their communities. 
Clinical Determinants of HIV Serostatus 
The findings indicated a significant association between aggregate use of HIV 
services and HIV serostatus for women in both age groups. This result neither confirmed 
nor refuted the findings reported by authors of systematic reviews, who implied that it 
was essential to conduct further studies to maximize prevention through the use of HIV 
medications (Mark et al., 2017; Williams, Renju, Ghilardi, & Wringe, 2017). However, 
there were no significant associations between HIV serostatus and the use of government 
services, clinic services, and NGO services considered individually. This finding agreed 
with the results of Mustapha, Musiime, Bakeera-Kitaka, Rujumba, and Nabukeera-
Barungi (2018) regarding the use of HIV services by women in Uganda. Those authors 
stated that HIV services for women were substandard in one sub-Saharan country, 
Uganda. Mustapha et al. (2018) reported that women received motivation to use services 
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from knowing HIV status and demotivation to use services from not knowing HIV 
serostatus, discrimination, and economic constraints. 
Authors of systematic studies described the benefits of team-based HIV service 
access for triggering improved HIV prevention in sub-Saharan African countries. 
Reviewers of quantitative and qualitative studies explicitly described associations 
between HIV serostatus and the use of team-based services versus institutionalized HIV 
services—government, clinic, and NGO (Mukumbang, Van Belle, Marchal, & Wyk, 
2017). The availability of HIV services in HIV-prone sub-Saharan African countries 
could be positive indicators of the containment of HIV spread and the deterrence of new 
infection. The use of HIV services in communities has the same level of importance. 
Along with HIV services, the implementation of precise HIV diagnostic tests to minimize 
false test outcomes is critical in sub-Saharan African countries (Kravitz et al., 2018). 
Demographic, Behavioral, and Clinical Determinants of HIV Serostatus 
Multivariate tests indicated no significant association between the synergistic 
association of  Demographic, Behavioral, and Clinical Determinants with HIV Serostatus 
for Zambian women aged 18–24. Likewise, there was no significant association between 
the synergistic association of  Demographic, Behavioral, and Clinical Determinants with 
HIV Serostatus for Zambian women aged 25 to 49. The community strategy outlined by 
health professionals, policymakers, and other entities involved in HIV prevention should 
be a collective drive to manage HIV epidemics in sub-Saharan Africa (Bibiana, 
Emmanuel, Amos, Ramsey, & Idris, 2018). The finding regarding the synergistic 
association between behavioral, demographic, and clinical determinants with HIV 
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serostatus could not address the recommendation by Kharsany and Karim (2016) for a 
study of behavioral determinants and the HIV literacy (education) gap with respect to 
HIV serostatus cognizance at the community level. 
The linkage between the Findings and the Conceptual Framework 
The World Health Organization’s Commission for Social Determinants of Health 
formed the conceptual framework used for this study. The commission addresses intrinsic 
disparities in HIV health between sub-Saharan Africa and the rest of the world. The 
framework emphasizes the complexity of behavioral, demographic, and clinical 
determinants and their role in HIV epidemics in this part of the globe. The study findings 
agreed with the strong associations of self-perceived HIV risk and educational attainment 
with HIV serostatus included in the framework. Other authors emphasized the impacts of 
health and academic literacy, race, age, and unsafe sexual practices on the acceleration of 
HIV infection (Araújo & Duarte, 2018). 
Limitations of the Study 
This study had certain limitations. The exclusion of those aged younger than 18 
years and older than 49 years, prisoners, and military personnel was one of the 
limitations. Because resource constraints dictated that the ZDHS surveyed only two 
provinces, the other eight provinces were excluded from data collection. The complete 
absence of men could be a significant limitation. Another limitation was that the study 
was cross-sectional rather than longitudinal. It lacked the benefits of conducting 
longitudinal research, including the ability to identify temporal effects and associated 
changes in the dynamics of sexual behaviors, demographic shifts, and capacity and 
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acceptability of HIV prevention services. The last limitation was the age of the data from 
the ZDHS. The laps of 10 years since the data were collected means that the data may not 
reflect the current situation. However, I could overcome this to some extent by 
extrapolating the findings through the lens of other consistent HIV research findings in 
sub-Saharan Africa. Generalization of the findings beyond the specific setting to other 
similar settings appears reasonable. 
Recommendations 
The recommendations in this section apply to Zambian women and women living 
in similar settings throughout sub-Saharan Africa. The consequences and risks of HIV 
prevail in older women. Future researchers can improve the robustness of their findings 
by including older women. Including this age group in HIV prevention efforts and will 
assist in significantly diminishing HIV in sub-Saharan Africa. According to Maughan-
Brown and Venkataramani (2018), the high prevalence of HIV in South Africa was due 
to risky sexual behaviors among older women. National and international collaboration 
are pivotal to lessen the spread of HIV throughout the world because HIV is a public 
health threat in every country. A unified approach to HIV prevention and control would 
have collateral health benefits when supported with measurable goals and comprehensive 
strategies (Baron et al., 2018; Jones, Sullivan, & Curran, 2019). 
Implications 
The dynamics of sexual behaviors and their associations with HIV serostatus 
indicate their impact on HIV prevalence, incidence, and epidemics in sub-Saharan Africa. 
One of the focuses was the paramount importance of the consolidation of leadership to 
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mobilize communities for harmonized HIV response (Fakoya, Dybul, & Sands, 2019). In 
conjunction with the findings on the associations of behavioral, demographic, and clinical 
determinants with HIV serostatus for Zambian women aged 18–49, the inclusion of 
female participants younger than 18 years and older than 49 years would yield more 
holistic findings that could be applied to fighting HIV (Rosenberg et al., 2017). 
Conclusion  
The findings regarding the associations of behavioral, demographic, and clinical 
determinants with HIV serostatus can be used to project risk, inform prevention efforts, 
and initiate longitudinal research. These findings suggest that self-perceived HIV risk, 
education, and type of HIV services are reliable indicators of HIV serostatus. The only 
difference between adolescent and adult Zambian women found was the synergistic 
association between HIV serostatus and behavioral, demographic, and clinical 
determinants, with a statistically significant association with the use of clinic services for 
women aged 25–49 and an association with the use of government services for women 
aged 18–24. 
Effective HIV prevention and control in sub-Saharan countries should focus on 
developing awareness using educational advancement as a tool, recognizing HIV risks 
through health literacy, and addressing social determinants of HIV health. These findings 
complement growing evidence indicating the benefits of collaborative HIV prevention 
efforts that involve HIV researchers and health professionals at both the local and 
international levels. The willingness of policymakers and government officials to allocate 
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resources and collaborate is a step toward the eradication of HIV, a goal that can only be 
reached with leadership from all entities and professionals related to HIV. 
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